WO2004047612A2 - Procédés de thérapie et de diagnostic - Google Patents

Procédés de thérapie et de diagnostic Download PDF

Info

Publication number
WO2004047612A2
WO2004047612A2 PCT/US2003/036971 US0336971W WO2004047612A2 WO 2004047612 A2 WO2004047612 A2 WO 2004047612A2 US 0336971 W US0336971 W US 0336971W WO 2004047612 A2 WO2004047612 A2 WO 2004047612A2
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia
acute
cell
cells
cell lymphoma
Prior art date
Application number
PCT/US2003/036971
Other languages
English (en)
Other versions
WO2004047612A3 (fr
Inventor
Douglas Dedera
Peter C. R. Emtage
Original Assignee
Nuvelo, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/302,444 external-priority patent/US20040022786A1/en
Priority claimed from US10/327,491 external-priority patent/US20040023870A1/en
Application filed by Nuvelo, Inc. filed Critical Nuvelo, Inc.
Priority to CA002506356A priority Critical patent/CA2506356A1/fr
Priority to EP03786850A priority patent/EP1567863A4/fr
Priority to AU2003295649A priority patent/AU2003295649A1/en
Publication of WO2004047612A2 publication Critical patent/WO2004047612A2/fr
Publication of WO2004047612A3 publication Critical patent/WO2004047612A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • This invention relates to compositions and methods for targeting Toll-like Receptor 10 (TLR10) protein-expressing cells and their use in the therapy and diagnosis of various pathological states, including cancer, autoimmune disease, organ transplant rejection, and allergic reactions.
  • TLR10 Toll-like Receptor 10
  • Antibody therapy for cancer involves the use of antibodies, or antibody fragments, against a tumor antigen to target antigen-expressing cells.
  • Antibodies, or antibody fragments may have direct or indirect cytotoxic effects or may be conjugated or fused to cytotoxic moieties.
  • Direct effects include the induction of apoptosis, the blocking of growth factor receptors, and anti-idiotype antibody formation.
  • Indirect effects include antibody- dependent cell-mediated cytotoxicity (ADCC) and complement-mediated cellular cytotoxicity (CMCC).
  • ADCC antibody- dependent cell-mediated cytotoxicity
  • CMCC complement-mediated cellular cytotoxicity
  • the antibodies, or fragments thereof provide a method of targeting the cytotoxicity towards the tumor antigen expressing cells.
  • tumor-specific antigens are found almost exclusively on tumors or are expressed at a greater level in tumor cells than the corresponding normal tissue.
  • Tumor-specific antigens provide targets for antibody targeting of cancer, or other disease-related cells, expressing the antigen.
  • Antibodies specific to such tumor-specific antigens can be conjugated to cytotoxic compounds or can be used alone in immuno therapy, hnmunotoxins target cytotoxic compounds to induce cell death.
  • anti-CD22 antibodies conjugated to deglycosylated ricin A may be used for treatment of B cell lymphoma that has relapsed after conventional therapy (Amlot, et al., Blood 82:2624-2633 (1993)) and has demonstrated encouraging responses in initial clinical studies.
  • Immunotherapy provides a method of harnessing the immune system to treat various pathological states, including cancer, autoimmune disease, transplant rejection, hyperproliferative conditions, and allergic reactions.
  • the immune system functions to eliminate organisms or cells that are recognized as non-self, including microorganisms, neoplasms and transplants.
  • a cell-mediated host response to tumors includes the concept of immunologic surveillance, by which cellular mechanisms associated with cell-mediated immunity, destroy newly transformed tumor cells after recognizing tumor-associated antigens (antigens associated with tumor cells that are not apparent on normal cells).
  • a humoral response to tumor-associated antigens enables destruction of tumor cells through immunological processes triggered by the binding of an antibody to the surface of a cell, such as antibody-dependent cellular cytotoxicity (ADCC) and complement mediated lysis.
  • ADCC antibody-dependent cellular cytotoxicity
  • an antigen by the immune system triggers a cascade of events including cytokine production, B-cell proliferation, and subsequent antibody production. Often tumor cells have reduced capability of presenting antigen to effector cells, thus impeding the immune response against a tumor-specific antigen. In some instances, the tumor-specific antigen may not be recognized as non-self by the immune system, preventing an immune response against the tumor-specific antigen from occurring. In such instances, stimulation or manipulation of the immune system provides effective techniques of treating cancers expressing one or more tumor-specific antigens.
  • Rituximab is a chimeric antibody directed against CD20, a B cell-specific surface molecule found on >95% of B-cell non-Hodgkin's lymphoma (Press, et al, Blood 69:584-591 (1987); Malony, et al, Blood 90:2188-2195 (1997)).
  • Rituximab induces ADCC and inhibits cell proliferation through apoptosis in malignant B cells in vitro
  • Rituximab is currently used as a therapy for advanced stage or relapsed low-grade non-Hodgkin's lymphoma, which has not responded to conventional therapy.
  • Active immunofherapy whereby the host is induced to initiate an immune response against its own tumor cells can be achieved using therapeutic vaccines.
  • One type of tumor- specific vaccine uses purified idiotype protein isolated from tumor cells, coupled to keyhole limpet hemocyanin (KLH) and mixed with adjuvant for injection into patients with low- grade follicular lymphoma (Hsu, et al, Blood 89:3129-3135 (1997)).
  • APCs antigen-presenting cells
  • Dendritic cells one type of APC, can be used in a cellular vaccine in which the dendritic cells are isolated from the patient, co-cultured with tumor antigen and then reinfused as a cellular vaccine (Hsu, et al, Nat. Med. 2:52-58 (1996)). Immune responses can also be induced by injection of naked DNA.
  • agents such as peptide fragments, nucleic acids, or antibodies that provide therapeutic compositions and diagnostic methods for treating and identifying cancer, hyperproliferative disorders, auto-immune diseases, and organ transplant rejection.
  • the invention provides therapeutic and diagnostic methods of targeting cells expressing the Toll-like Receptor 10 (TLR10) protein by using targeting elements such as TLR10 polypeptides, nucleic acids encoding TLR10 protein, and anti-TLRlO antibodies, including fragments or other modifications thereof, peptides, and small molecules.
  • TLR10 proteins are highly expressed in certain hematopoietic-based cancer cells relative to their expression in healthy cells. Additionally, TLR10 mRNA is highly expressed in neutrophils. Thus, targeting of cells that express TLR10 will have a minimal effect on healthy tissues while destroying or inhibiting the growth of the hematopoietic-based cancer cells and/or neutrophils.
  • non-hematopoietic type tumors can be targeted if they bear the TLRIO antigen.
  • TLRIO protein is highly expressed in solid tumors, such as prostate, breast, colon and squamous cell carcinoma.
  • inhibition of growth and/or destruction of TLRlO-expressing cancer cells results from targeting such cells with anti-TLRl 0 antibodies, respectively.
  • One embodiment of the invention is a method of destroying TLRlO-expressing cells by conjugating anti-TLRl 0 antibodies with cytocidal materials such as radioisotopes or other cytotoxic compounds, respectively.
  • the present invention provides a variety of targeting elements and compositions.
  • One such embodiment is a composition comprising an anti-TLRl 0 antibody preparation.
  • Exemplary antibodies include a single anti-TLRl 0 antibody, a combination of two or more anti-TLRl 0 antibodies, a combination of an anti-TLRl 0 antibody with a non-TLRl 0 antibody, a combination of an anti-TLRl 0 antibody and a therapeutic agent, a combination of an anti-TLRl 0 antibody and a cytocidal agent, a bispecific anti-TLRl 0 antibody, Fab TLRIO antibodies or fragments thereof, including any fragment of an antibody that retains one or more complementary determining regions (CDRs) that recognize TLRIO, humanized anti-TLRl 0 antibodies that retain all or a portion of a CDR that recognizes TLRl 0, anti- TLRl 0 conjugates, and anti-TLRl 0 antibody fusion proteins.
  • CDRs complementary determining regions
  • Another targeting embodiment of the invention is a composition comprising a TLRIO antigen, for example a TLRIO polypeptide, or a fragment thereof and optionally comprising a suitable adjuvant.
  • a preparation comprising a TLRIO antigen, for example a TLRIO polypeptide, or a fragment thereof and optionally comprising a suitable adjuvant.
  • TLR10 polypeptide, or peptide fragment A further targeting embodiment of the present invention is a non-TLRl 0 polypeptide or peptide that binds TLR10.
  • Another targeting embodiment of the invention is a preparation comprising a small molecule that recognizes TLR10.
  • Yet another targeting embodiment is a composition comprising a nucleic acid encoding TLR10, or a fragment or variant thereof, optionally within a recombinant vector.
  • a further targeting embodiment of the present invention is a composition comprising an antigen-presenting cell transformed with a nucleic acid encoding TLR10, or a fragment or variant thereof, optionally within a recombinant vector.
  • the present invention further provides a method of targeting TLRl 0-expressing cells, which comprises administering a targeting element or composition in an amount effective to target TLRlO-expressing cells.
  • any one of the targeting elements or compositions described herein may be used in such methods, including an anti-TLRl 0 antibody preparation, an antigen comprising a TLRIO polypeptide, or a fragment thereof or a composition of a nucleic acid encoding TLRIO, or a fragment thereof, optionally within a recombinant vector or a composition of an antigen-presenting cell transformed with a nucleic acid encoding
  • TLRIO or fragment or variant thereof, optionally within a recombinant vector, or a TLRIO polypeptide, peptide fragment, or a binding polypeptide, peptide or small molecule that binds TLRIO.
  • the invention also provides a method of inhibiting the growth of hematopoetic- based, TLRlO-expressing cancer cells, which comprises administering a targeting element or a targeting composition in an amount effective to inhibit the growth of said hematopoetic- based cancer cells.
  • any one of the targeting elements or compositions described herein may be used in such methods, including an anti-TLRl 0 antibody preparation, an antigen comprising a TLRIO polypeptide, or fragment thereof, composition of a nucleic acid encoding TLRIO, or fragment or variant thereof, optionally within a recombinant vector, or a composition of an antigen-presenting cell transformed with a nucleic acid encoding TLRIO, or fragment or variant thereof, optionally within a recombinant vector, or a TLRIO polypeptide, peptide fragment, or a binding polypeptide, peptide or small molecule that binds TLRIO.
  • the present invention further provides a method of treating disorders associated with the proliferation of TLRl 0-expressing cells in a subject in need thereof, comprising the step of administering a targeting element or targeting composition in a therapemicaUy effective amount to treat disorders associated with TLRlO-expressing cells.
  • any one of the targeting elements or compositions described herein may be used in such methods, including an anti- TLRl 0 antibody preparation, an antigen comprising a TLR10 polypeptide or fragment thereof, a composition of a nucleic acid encoding TLR10, or fragment thereof, optionally within a recombinant vector, or a composition of an antigen-presenting cell comprising a nucleic acid encoding TLR10, or fragment thereof, optionally within a recombinant vector.
  • disorders associated with the proliferation of TLRlO-expressing cells include cancers, such as non-Hodgkin's B-cell lymphomas, B-cell leukemias, chronic lymphocytic leukemia, multiple myeloma, acute and chronic myeloid leukemia; myelodysplastic syndromes; T cell lymphomas, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, lymphosarcoma leukemia, malignant lymphoma, B cell large cell lymphoma, X-linked lymphoproliferative disorders; Epstein Barr Virus-related conditions such as mononucleosis; and autoimmune disorders.
  • cancers such as non-Hodgkin's B-cell lymphomas, B-cell leukemias, chronic lymphocytic leukemia, multiple myeloma, acute and chronic myeloid leukemia; myelodysplastic syndromes
  • Non-hematopoietic tumors that bear the TLRl 0 antigen such as prostate, breast, colon, and squamous cell carcinoma, as well as other cancers of epithelial and squamous cell origin, can also be targeted.
  • disorders associated with neutrophils include, but are not limited to, inflammatory disorders, autoimmune diseases, asthma, chronic pancreatitis, allergic dermatitis, idiopathic pulmonary fibrosis, upper and lower respiratory infection, acute pulmonary inflammation, wound healing, graft vs. host disease, chronic obstructive pulmonary disease, arthritis, periodontitis, and disorders relating to oxidative stress, including hypertension pathogenesis and athlerosclerosis.
  • the invention further provides a method of modulating the immune system by either suppression or stimulation of growth factors and cytokines, by administering the targeting elements or compositions of the invention.
  • the invention also provides a method of modulating the immune system through activation of immune cells (such as natural killer cells, T cells, B cells and myeloid cells), through the suppression of activation, or by stimulating or suppressing proliferation of these cells by TLRIO peptide fragments or TLRIO antibodies.
  • immune cells such as natural killer cells, T cells, B cells and myeloid cells
  • the present invention thereby provides a method of treating immune-related disorders by suppressing the immune system in a subject in need thereof, by administering the targeting elements or compositions of the invention.
  • immune-related disorders include but are not limited to autoimmune disease and organ transplant rejection.
  • the present invention also provides a method of diagnosing disorders associated with TLRlO-expressing cells comprising the step of measuring the expression patterns of TLR10 protein and/or mRNA, respectively. Yet another embodiment of a method of diagnosing disorders associated with TLRlO-expressing cells comprising the step of detecting TLR10 expression using anti-TLRl 0 antibodies, respectively.
  • Such methods of diagnosis include compositions, kits and other approaches for determining whether a patient is a candidate for TLR10 targeting therapy.
  • the present invention also provides a method of enhancing the effects of therapeutic agents and adjunctive agents used to treat and manage disorders associated with TLRlO- expressing cells, by administering TLR10 preparations with therapeutic and adjuvant agents commonly used to treat such disorders. 4. BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 depicts the relative expression of TLRIO mRNA (as determined by RT-
  • PCR derived from leukocytes and leukocyte progenitors.
  • the present invention relates to methods of targeting cells that express TLRIO using targeting elements, such as TLRIO polypeptides, nucleic acids encoding TLRIO, anti-TLRl 0 antibodies, binding polypeptides, peptides, and small molecules, including fragments or other modifications of any of these elements.
  • the present invention provides a novel approach for diagnosing and treating diseases and disorders associated with TLRlO-expressing cells.
  • the method comprises administering an effective dose of targeting preparations such as TLRIO antigens, antigen presenting cells, or pharmaceutical compositions comprising the targeting elements, TLRIO polypeptides, nucleic acids encoding TLRIO, anti-TLRl 0 antibodies, or binding polypeptides, peptides, and small molecules, described below.
  • Targeting of TLRl 0 on the cell membranes of TLRlO-expressing cells, respectively, is expected to inhibit the growth of or destroy such cells.
  • An effective dose will be the amount of such targeting TLRl 0 preparations necessary to target the TLRIO on the cell membrane and inhibit the growth of or destroy the TLRlO- expressing cells and/or metastasis.
  • a further embodiment of the present invention is to enhance the effects of therapeutic agents and adjunctive agents used to treat and manage disorders associated with TLRlO- expressing cells, by administering TLRIO preparations, respectively, with therapeutic and adjuvant agents commonly used to treat such disorders.
  • Chemotherapeutic agents useful in treating neoplastic disease and antiproliferative agents and drugs used for immunosuppression include alkylating agents, such as nitrogen mustards, allcyl sulfonates, nitrosoureas, triazenes; antimetabolites, such as folic acid analogs, pyrimidine analogs, and purine analogs; natural products, such as vinca alkaloids, epipodophyllotoxins, antibiotics, and enzymes; miscellaneous agents such as polatinum coordination complexes, substituted urea, methyl hydrazine derivatives, and adrenocortical suppressant; and hormones and antagonists, such as adrenocorticosteroids, progestins, estrogens, androgens, and anti- estrogens (Calebresi and Parks, pp.
  • alkylating agents such as nitrogen mustards, allcyl sulfonates, nitrosoureas, triazenes
  • Adjunctive therapy used in the management of such disorders includes, for example, radiosensitizing agents, coupling of antigen with heterologous proteins, such as globulin or beta-galactosidase, or inclusion of an adjuvant during immunization.
  • High doses may be required for some therapeutic agents to achieve levels to effectuate the target response, but may often be associated with a greater frequency of dose- related adverse effects.
  • combined use of the therapeutic methods of the present invention with agents commonly used to treat TLRIO protein-related disorders allows the use of relatively lower doses of such agents resulting in a lower frequency of adverse side effects associated with long-term administration of the conventional therapeutic agents.
  • Another indication for the therapeutic methods of this invention is to reduce adverse side effects associated with conventional therapy of disorders associated with TLRlO- expressing cells.
  • fragment of a nucleic acid refers to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 11 nucleotides and most preferably at least about 17 nucleotides.
  • the fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides.
  • the fragments can be used in polymerase chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules.
  • a fragment or segment may uniquely identify each polynucleotide sequence of the present invention.
  • the fragment comprises a sequence substantially similar to a portion of SEQ ID NO: 1.
  • a polypeptide "fragment" is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids.
  • the peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids.
  • the peptide is from about 5 to about 200 amino acids.
  • any polypeptide must have sufficient length to display biological and/or immunological activity.
  • immuno genie refers to the capability of the natural, recombinant or synthetic TLRIO peptide, or any peptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.
  • variant refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e g., recombinant DNA techniques.
  • Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology
  • TLRIO antigen refers to a molecule that when introduced into an animal is capable of stimulating an immune response in said animal specific to the TLRIO polypeptide or fragment thereof, of the present invention.
  • stringent is used to refer to conditions that are commonly understood in the art as stringent.
  • Stringent conditions can include highly stringent conditions ⁇ i.e., hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 iiiM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C), and moderately stringent conditions ⁇ i.e., washing in 0.2x SSC/0.1% SDS at 42°C).
  • SDS sodium dodecyl sulfate
  • moderately stringent conditions ⁇ i.e., washing in 0.2x SSC/0.1% SDS at 42°C.
  • Other exemplary hybridization conditions are described herein in the examples.
  • additional exemplary stringent hybridization conditions include washing in 6* SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligonucleotides), 48°C (for 17-base oligonucleotides), 55°C (for 20- base oligonucleotides), and 60°C (for 23-base oligonucleotides).
  • Toll and Toll-like receptors are type I transmembrane proteins with extracellular leucine-rich repeat motifs and an intracellular signaling domains.
  • the Toll-like receptors make up a family of human receptors which have common structural features with the Drosophila Toll (dToll) receptor molecule. They are found on the surface of several types of hematopoietic cells. Human Toll-like receptors are also expressed on antigen presenting cells, such as monocytes and dendritic cells (WO 01/55386 Al).
  • Toll-like receptors Both dToll and human Toll-like receptors are thought to act as pattern recognition receptors for bacteria and other microorganisms, and play a role in immune surveillance mechanisms and innate immunity. Toll-like receptors can trigger pro-inflammatory cytokine production and induce expression of cell surface co-stimulatory receptors for T-cell activation. Some human Toll-like receptors may be involved in co-ordination of interactions between immune cells resulting in an integrated immune response to infection. TLR2 and TLR4 have been shown to mediate host responses to gram positive and gram negative bacteria through recognition of specific bacterial wall components. TLR4 mediates responses to certain viral proteins such as respiratory syncytial virus.
  • Toll-like receptors may also form heterodimeric functional complexes and share in common signal transduction pathways with IL-1 receptors.
  • Activation of TLR2 and TLR4 leads to the activation of NFKB via an adapter protein MyD88 and recruitment of the IL-1 receptor - associated kinases (IRAKs) (WO 01/55386 Al; Henneke and Golenbock, Nature Immunology/ 2:828- 830 (2001))
  • Toll-like Receptor 9 (TLR9) was shown to mediate the cellular response to bacterial deoxy-cytidylate-phosphate-deoxyguanylate (CpG) DNA, suggesting that vertebrate systems have evolved a specific Toll-like receptor that distinguishes bacterial DNA from self-DNA (Hemml, et al, Nature 408:740-744 (2000); Bauer, et al, Proc.
  • CpG DNA may be recognized by autoantibodies inducing an autoimmune response (Ichikawa et al, J. Immunol. 169:2781- 2787 (2002); Leadbetter et al, Nature 416:603-607 (2002), both are herein incorporated by reference).
  • TLR10 a new member of the TLR family, is most closely related to TLRl and TLR6 (Chuang and Ulevitch, Biochim, Biophys, Acta 1518:157-161 (2001), herein incorporated by reference).
  • TLRl and TLR6 Chuang and Ulevitch, Biochim, Biophys, Acta 1518:157-161 (2001), herein incorporated by reference.
  • the cytoplasmic domains of TLRl and TLR6 have been demonstrated to form functional pairs with TLR2, thus TLR10 may also interact with TLR2
  • TLR10 polypeptides and polynucleotides encoding such polypeptides are disclosed in co-owned U.S. Patent Application Serial No. 09/488,725, which corresponds to PCT Publication No. WO 01/53455, incorporated herein by reference, which relates, in general, to a collection or library of at least one novel nucleic acid sequences, specifically contigs, assembled from expressed sequence tags (ESTs).
  • ESTs expressed sequence tags
  • PCT International Publication No. WO 01/55386 discloses a novel Toll-like receptor and its use in screening for novel pharmacotherapeutic agents with immunomodulatory activity. More specifically, WO 01/55386 discloses isolated Toll-like receptor polypeptides, polynucleotides encoding for the Toll-like receptor polypeptide, expression vectors comprising such polynucleotides, hosts cells comprising such expression vectors, antibodies specific for the Toll-like receptor polypeptide, methods for identification of compounds that modulate Toll-like receptor activity, and methods of treating disorders responsive to toll-like receptor modulation.
  • PCT International Publication No. WO 01/55386 discloses a novel Toll-like receptor and its use in screening for novel pharmacotherapeutic agents with immunomodulatory activity. More specifically, WO 01/55386 discloses isolated Toll-like receptor polypeptides, polynucleotides encoding for the Toll-like receptor polypeptide, expression vectors comprising such polynucleotides, hosts cells
  • 99/20756 discloses human Toll homolog polypeptides, polynucleotides encoding for the human Toll homologs, expression vectors comprising such polynucleotides, host cells comprising such expression vectors, antibodies specific for the human Toll homolog polypeptides, antibodies that specifically bind to a human TLR2 receptor, and methods for treating septic shock using anti-Toll homolog antibodies.
  • Table 1 shows that TLR10 was found to be expressed at high levels in the B cell lymphoma cell lines CA-46 and RA1, moderately expressed in the B cell lymphoma cell lines DB, HT, and RL. These results demonstrate that TLR10 mRNA is highly expressed in cell lines derived from B cell lymphomas.
  • the results in Table 2 show that levels of mRNA expression were high in foUicular lymphoma tissue (L5856 and L5348), moderate in diffuse large B cell lymphoma tissue (L6879 and L22601), and anaplastic large T cell lymphoma tissue (L5664), and low in acute myeloid leukemia tissue (AML565).
  • TLR10 mRNA expression in different Non-Hodgkin's B cell lymphoma tissues and cell lines demonstrate that TLRIO may be used as an immunotherapeutic antibody target and a diagnostic marker for certain cell types or disorders ⁇ e.g., B-cell lymphomas, T cell lymphomas, and myeloid leukemia).
  • TLRIO is expressed in the following leukemias and lymphomas: acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, and lymphosarcoma cell leukemia.
  • leukemias and lymphomas include acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, and lymphosarcoma cell leukemia.
  • TLRIO is also expressed in solid tumors, such as prostate, breast, colon and squamous cell carcinoma (see Table 4).
  • TLRIO Since TLRIO is expressed in these epithelial and squamous cell cancers, it is likely that TLRIO will be expressed in other cancers of epithelial and squamous cell origin. LHC analysis showed that TLRIO is also expressed in autoimmune disorders, including systemic lupus erythematosus; Hasimoto thyroiditis, Sjorgen's syndrome, and pericarditis lupus (see Table 5). Therefore, targeting TLRIO may be useful in treating these and other autoimmune disorders. Finally, IHC analysis showed that TLRIO is expressed in rejected transplanted heart, kidney and liver tissues, whereas normal tissues do not express TL'RIO (see Table 6). Thus, targeting TLRIO will be useful in reducing and/or eliminating tissue rejection after transplantation.
  • Leukocytes including neutrophils
  • neutrophils are recruited to sites of infection and injury in the early stages of the inflammatory pathway. Normally, unwanted effector cells are cleared at the end of the inflammatory response presumably due to the loss of survival signals.
  • the resolution phase becomes prolonged and disordered leading to the persistence of inflammatory infiltrate ⁇ i.e. neutrophils), tissue hyperplasia, and ultimately tissue scarring (Buckley, Rheumatology 42:1-12 (2003); Simon, Immunol. Rev. 193:101-110 (2003), both of which are herein incorporated by reference in their entirety).
  • edema can cause capillary plugging, thereby impeding blood flow resulting in the no-flow phenomenon (Gravlee 2000 supra; Ambrosio 1999 supra; Byrne et al, J. Thorac. Cardiovasc. Surg. 104:1589-1596 (1992) all of which are herein incorporated by reference in their entirety).
  • removal of the neutrophils would decrease the risk of reperfusion injury and transplantation rejection.
  • disorders that are characterized by chronic inflammation such as autoimmune diseases, allergic reactions, asthma, wound healing, graft vs. host disease, and the like would benefit from therapies that target the excess neutrophils for clearance.
  • TLR10 mRNA is highly expressed in neutrophils; therefore TLR10 targeting compositions may be effective in treating disorders which are characterized by aberrant levels of neutrophils.
  • one embodiment of the present invention provides a composition comprising a TLR10 antigen, for example a polypeptide, to stimulate the immune system against TLR10, thus targeting TLRlO-expressing cells.
  • a tumor antigen in a composition for generating cellular and humoral immunity for the purpose of anti-cancer therapy is well known in the art.
  • one type of tumor-specific antigen composition uses purified idiotype protein isolated from tumor cells, coupled to keyhole limpet hemocyanin (KLH) and mixed with adjuvant for injection into patients with low-grade foUicular lymphoma (Hsu, et al, Blood 89: 3129-3135 (1997)).
  • KLH keyhole limpet hemocyanin
  • U.S. Patent No. 6,312,718 describes methods for inducing immune responses against malignant B cells, in particular lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
  • the methods described therein utilize vaccines that include liposomes having (1) at least one B-cell malignancy-associated antigen, (2) IL-2 alone, or in combination with at least one other cytokine or chemokine, and (3) at least one lipid molecule.
  • Methods of targeting TLR10 using a TLR10 antigen typically employ a TLR10 polypeptide, including fragments, analogs and variants.
  • dendritic cells one type of antigen-presenting cell, can be used in a cellular vaccine in which the dendritic cells are isolated from the patient, co-cultured with tumor antigen and then reinfused as a cellular vaccine (Hsu, et al., Nat. Med. 2:52-58
  • a nucleic acid encoding TLRIO, or encoding a fragment, analog or variant thereof, within a recombinant vector is utilized.
  • Such methods are known in the art.
  • immune responses can be induced by injection of naked DNA. Plasmid DNA that expresses bicistronic mRNA encoding both the light and heavy chains of tumor idiotype proteins, such as those from B cell lymphoma, when injected into mice, are able to generate a protective, anti-tumor response (Singh, et al, Vaccine 20: MOO- I 1 (2002)).
  • TLR10 viral vectors are particularly useful for delivering TLRlO-encoding nucleic acids to cells, respectively.
  • vectors include those derived from influenza, adenovirus, vaccinia, herpes symplex virus, fowlpox, vesicular stomatitis virus, canarypox, poliovirus, adeno-associated virus, and lentivirus and Sindbus virus.
  • non- viral vectors such as liposomes or even naked DNA, are also useful for delivering TLRlO-encoding nucleic acids to cells.
  • a vector comprising a nucleic acid encoding the TLR10 polypeptide is introduced into a cell, such as a dendritic cell or a macrophage.
  • a cell such as a dendritic cell or a macrophage.
  • TLR10 antigens are presented to T cells eliciting an immune response against TLR10.
  • Such methods are also known in the art. Methods of introducing tumor antigens into antigen presenting cells and vectors useful therefor are described in U.S. Patent No. 6,300,090.
  • the vector encoding TLR10 maybe introduced into the antigen presenting cells in vivo.
  • antigen-presenting cells are loaded with TLR10 or a nucleic acid encoding TLRIO ex vivo and then introduced into a patient to elicit an immune response against TLRIO, respectively.
  • the cells presenting TLRIO antigen are used to stimulate the expansion of anti-TLRl 0 cytotoxic T lymphocytes (CTL) ex vivo followed by introduction of the stimulated CTL into a patient.
  • CTL cytotoxic T lymphocytes
  • antisense nucleic acid molecules that can hybridize to, or are complementary to, the nucleic acid molecule comprising the TLR10 nucleotide sequence, or fragments, analogs or derivatives thereof.
  • An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence).
  • antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire TLR10 coding strand, or to only a portion thereof.
  • Nucleic acid molecules encoding fragments, homo logs, derivatives and analogs of a TLR10 or antisense nucleic acids complementary to a TLR10 nucleic acid sequence of are additionally provided.
  • an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a TLR10 protein.
  • the term "coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues
  • the antisense nucleic acid molecule is antisense to a "conceding region" of the coding strand of a nucleotide sequence encoding the TLR10 protein.
  • the term "conceding region” refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids ⁇ i.e., also referred to as 5' and 3' untranslated regions).
  • antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing.
  • the antisense nucleic acid molecule can be complementary to the entire coding region of TLR10 mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of TLR10 mRNA.
  • the antisense oligonucleotide can be complementary to the region surrounding the translation start site of TLRIO mRNA.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length.
  • An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid ⁇ e.g., an antisense oligonucleotide
  • an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids ⁇ e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).
  • modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5- carboxymethylaniinomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3- methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5- methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-meth
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation ⁇ i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following section).
  • the antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a TLR10 protein to thereby inhibit expression of the protein ⁇ e.g., by inhibiting transcription and/or translation).
  • the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix.
  • An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site.
  • antisense nucleic acid molecules can be modified to target selected cells and then administered systemically.
  • antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface ⁇ e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens).
  • the antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
  • the antisense nucleic acid molecule of the invention is an alpha-anomeric nucleic acid molecule.
  • An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual alpha-units, the strands run parallel to each other. See, e.g., Gaultier, et al, Nucl Acids Res. 15: 6625-6641 (1987).
  • the antisense nucleic acid molecule can also comprise a 2'-o- methylribonucleotide (see, e.g., Inoue, et al, Nucl. Acids Res.
  • RNA-DNA analogue see, e.g., Inoue, et al, FEBS Lett. 215: 327-330 (1987), all of which are herein incorporated by reference in their entirety.
  • an antisense nucleic acid of the invention is a ribozyme.
  • Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
  • ribozymes ⁇ e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of an mRNA.
  • a ribozyme having specificity for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein ⁇ i.e., SEQ ID NO: 1).
  • a derivative of Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA.
  • mRNA of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from apool of RNA molecules. See, e.g., Bartel et al, (1993) Science 261:1411-1418.
  • gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region ⁇ e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells.
  • nucleotide sequences complementary to the regulatory region e.g., promoter and/or enhancers
  • the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule.
  • the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorg Med Chem 4: 5-23).
  • the tenns "peptide nucleic acids" or "PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
  • PNAs The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
  • the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) above; Perry-O'Keefe et al. (1996) PNAS 93: 14670-675.
  • PNAs of the invention can be used in therapeutic and diagnostic applications.
  • PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g. , inducing transcription or translation arrest or inhibiting replication.
  • PNAs of the invention can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., SI nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O'Keefe (1996), above).
  • PNAs of the invention can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.
  • PNA-DNA chimeras can be generated that may combine the advantageous properties of PNA and DNA.
  • Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity.
  • PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above).
  • the synthesis of PNA-DNA chimeras can be performed as described in Hyrup
  • a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag et al. (1989)
  • PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al.
  • chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen et al. (1975) Bioorg Med Chem Lett 5: 1119-11124.
  • the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al, 1989, Proc. Natl Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al, 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134).
  • peptides e.g., for targeting host cell receptors in vivo
  • agents facilitating transport across the cell membrane see, e.g., Letsinger et al, 1989, Proc. Natl Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al, 1987, Proc. Nat
  • oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol et al, 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5: 539-549).
  • the oligonucleotide maybe conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.
  • Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein.
  • the invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention.
  • Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, 392(Suppl):25-20 (1998).
  • polypeptides of the invention in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.
  • RNA sequences are known in the art.
  • the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.
  • the present invention still further provides cells genetically engineered in vivo to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.
  • DNA sequences allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide.
  • Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels.
  • the heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955, all of which are incorporated by reference in their entirety.
  • amplifiable marker DNA e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase
  • intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co- amplification of the desired protein coding sequences in the cells.
  • cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination.
  • gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods.
  • Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences.
  • sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.
  • the targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enliancer or both upstream of a gene.
  • the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element.
  • the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell- type specificity than the naturally occurring elements.
  • the naturally occurring sequences are deleted and new sequences are added.
  • the identification of the targeting event maybe facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome.
  • the identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker.
  • Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.
  • TLR10 targeting involves the administration of components of the immune system, such as antibodies, antibody fragments, or primed cells of the immune system against the target.
  • components of the immune system such as antibodies, antibody fragments, or primed cells of the immune system against the target.
  • Methods of targeting cancer cells using antibodies or antibody fragments are well known in the art.
  • U.S. Patent No. 6,306,393 describes the use of anti- CD22 antibodies in the immunotherapy of B-cell malignancies
  • U.S. Patent No. 6,329,503 describes immunotargeting of cells that express serpentine transmembrane antigens.
  • TLR10 antibodies may be introduced into a patient such that the antibody binds to TLR10 expressed by cancer cells and mediates the destruction of the cells and the tumor and/or inhibits the growth of the cells or the tumor.
  • mechanisms by which such antibodies can exert a therapeutic effect may include complement-mediated cytolysis, antibody-dependent cellular cytotoxicity (ADCC), modulating the physiologic function of TLR10, inhibiting binding or signal transduction pathways, modulating tumor cell differentiation, altering tumor angiogenesis factor profiles, modulating the secretion of immune stimulating or tumor suppressing cytokines and growth factors, modulating cellular adhesion, and/or by inducing apoptosis.
  • TLR10 antibodies conjugated to toxic or therapeutic agents, such as radioligands or cytosolic toxins, may also be used therapeutically to deliver the toxic or therapeutic agent directly to TLRlO-bearing tumor cells.
  • TLR10 antibodies may be used to suppress the immune system in patients receiving organ transplants or in patients with autoimmune diseases such as arthritis. Healthy immune cells would be targeted by these antibodies leading their death and clearance from the system, thus suppressing the immune system.
  • TLRIO antibodies maybe used as antibody therapy for solid tumors which express this action. Cancer immunotherapy using antibodies provides a novel approach to treating cancers associated with cells that specifically express TLRIO. As described above, human
  • Toll-like receptors were shown to be expressed on antigen presenting cells, such as monocytes and dendritic cells (WO 01/55386 Al), human colon cancer cell lines (DLD and
  • TLR10 was found to be expressed at high levels in the B cell lymphoma cell lines CA-46 and RAl, and moderately expressed in the B cell lymphoma cell lines DB, HT, and RL. These results demonstrate that TLR10 mRNA is highly expressed in cell lines derived from B cell lymphomas.
  • TLRl 0 is expressed in the following leukemias and lymphomas: acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lyrnphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, and lymphosarcoma cell leukemia.
  • TLR10 is also expressed in solid tumors, such as prostate, breast, colon and squamous cell carcinoma (see Table 4); therefore, targeting TLR10 may be useful to treat these and other non-hematopoietic type tumors (solid tumors).
  • TLR10 antibody therapy may be useful for all stages of the foregoing cancers, antibody therapy may be particularly appropriate in advanced or metastatic cancers. Combining the antibody therapy method with a chemotherapeutic, radiation or surgical regimen may be preferred in patients that have not received chemotherapeutic treatment, whereas treatment with the antibody therapy may be indicated for patients who have received one or more chemotherapies. Additionally, antibody therapy can also enable the use of reduced dosages of concomitant chemotherapy, particularly in patients that do not tolerate the toxicity of the chemotherapeutic agent very well. Furthermore, treatment of cancer patients with TLRIO antibodies with tumors resistant to chemotherapeutic agents might induce sensitivity and responsiveness to these agents in combination. Prior to TLRIO targeting, a patient may be evaluated for the presence and level of
  • TLRIO expression by the cancer cells preferably using immunohistochemical assessments of tumor tissue, quantitative TLRIO imaging, quantitative RT-PCR, or other techniques capable of reliably indicating the presence and degree of TLRIO expression.
  • a blood or biopsy sample may be evaluated by immunohistochemical methods to determine the presence of TLRl 0-expressing cells or to determine the extent of TLRl 0 expression on the surface of the cells within the sample. Methods for immunohistochemical analysis of tumor tissues or released fragments of TLRIO in the serum are well known in the art.
  • Anti-TLRl 0 antibodies useful in treating cancers include those, which are capable of initiating a potent immune response against the tumor and those, which are capable of direct cytotoxicity.
  • anti-TLRl 0 mAbs may elicit tumor cell lysis by either complement-mediated or ADCC mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins.
  • anti-TLRl 0 antibodies that exert a direct biological effect on tumor growth are useful in the practice of the invention. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis.
  • the mechanism by which a particular anti-TLRl 0 antibody exerts an anti- tumor effect may be evaluated using any number of in vitro assays designed to determine ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.
  • the anti-tumor activity of a particular anti-TLRl 0 antibody, or combination of anti- TLRl 0 antibody may be evaluated in vivo using a suitable animal model.
  • a suitable animal model For example, xenogenic lymphoma cancer models wherein human lymphoma cells are introduced into immune compromised animals, such as nude or SCID mice. Efficacy may be predicted using assays, which measure inhibition of tumor formation, tumor regression or metastasis, and the like.
  • Anti-TLRl 0 antibodies can also be used to target non-cancer cells that express TLR10.
  • TLR10 is expressed in autoimmune disorders (see Table 5), in rejected transplanted tissue (see Table 6), and in neutrophils (see Figure 1). Therefore, targeting cells expressing TLRIO can be used in treating autoimmune disorders, reducing and/or eliminating tissue rejection after transplantation, and in neutrophil-associated disorders.
  • murine or other non-human monoclonal antibodies, human/mouse chimeric mAbs may induce moderate to strong immune responses in some patients. In the most severe cases, such an immune response may lead to the extensive formation of immune complexes, which, potentially, can cause renal failure.
  • preferred monoclonal antibodies used in the practice of the therapeutic methods of the invention are those which are either fully human or humanized and which bind specifically to the target TLRIO antigen with high affinity but exhibit low or no antigenicity in the patient.
  • the method of the invention contemplates the administration of single anti-TLRl 0 monoclonal antibodies (mAbs) as well as combinations, or "cocktails", of different mAbs.
  • mAbs monoclonal antibodies
  • Two or more monoclonal antibodies that bind to TLRl 0 may provide an improved effect compared to a single antibody.
  • a combination of an anti-TLRl 0 antibody with an antibody that binds a different antigen may provide an improved effect compared to a single antibody.
  • Such mAb cocktails may have certain advantages inasmuch as they contain mAbs, which exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination may exhibit synergistic therapeutic effects.
  • anti-TLRl 0 mAbs may be combined with other therapeutic agents, including but not limited to various chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL-2, GM-CSF).
  • the anti-TLRl 0 mAbs may be administered in their "naked” or unconjugated form, or may have therapeutic agents conjugated to them.
  • bispecific antibodies may be used. Such an antibody would have one antigenic binding domain specific for TLR10 and the other antigenic binding domain specific for another antigen (such as CD20 for example).
  • Fab TLR10 antibodies or fragments of these antibodies may also be used as therapeutic agents.
  • Antibodies that specifically bind TLR10 are useful in compositions and methods for immunotargeting cells expressing TLR10 and for diagnosing a disease or disorder wherein cells involved in the disorder express TLR10.
  • Such antibodies include monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region
  • CDR-grafted antibodies including compounds that include CDR and/or antigen-binding sequences, which specifically recognize TLRIO.
  • Antibody fragments including Fab, Fab',
  • F(ab') 2 , and F v are also useful.
  • the term "specific for” indicates that the variable regions of the antibodies recognize and bind TLRIO exclusively ⁇ i.e., able to distinguish TLRIO from other similar polypeptides despite sequence identity, homo logy, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, S. aureus protein A or other antibodies in
  • TLRIO polypeptides can be used to immunize animals to obtain polyclonal and monoclonal antibodies that specifically react with TLRIO, respectively. Such antibodies can be obtained using either the entire protein or fragments thereof as an immunogen.
  • the peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH).
  • KLH keyhole limpet hemocyanin
  • Any animal capable of producing antibodies can be immunized with a TLR10 peptide or polypeptide.
  • Methods for immunization include subcutaneous or intraperitoneal injection of the polypeptide.
  • the amount of the TLR10 peptide or polypeptide used for immunization depends on the animal that is immunized, antigenicity of the peptide and the site of injection.
  • the TLR10 peptide or polypeptide used as an immunogen may be modified or administered in an adjuvant in order to increase the protein's antigenicity.
  • Methods of increasing the antigenicity of a protein include, but are not limited to, coupling the antigen with a heterologous protein (such as globulin or ⁇ - galactosidase) or through the inclusion of an adjuvant during immunization.
  • a heterologous protein such as globulin or ⁇ - galactosidase
  • spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/0-Agl4 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells.
  • myeloma cells such as SP2/0-Agl4 myeloma cells
  • Any one of a number of methods well known in the art can be used to identify the hybridoma cell that produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay,
  • antibody-containing antiserum is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures.
  • the anti-TLRl 0 antibody can be a nonhuman primate antibody. Methods of making such antibodies in baboons are disclosed in WO 91/11465 and Losman et al., Int. J. Cancer 46:310-314 (1990).
  • the anti-TLRlO antibody is a humanized monoclonal antibody. Methods of producing humanized antibodies have been previously described. (U.S. Patent Nos.
  • the anti-TLRl 0 antibody is a human monoclonal antibody. Humanized antibodies are produced by transgenic mice that have been engineered to produce human antibodies.
  • Hybridomas derived from such mice will secrete large amounts of human monoclonal antibodies.
  • Methods for obtaining human antibodies from transgenic mice are described in Green, et al, Nature Genet. 7:13-21 (1994), Lonberg, et al, Nature 368:856 (1994), and Taylor, et al, Int. Immun. 6:579 (1994).
  • the present invention also includes the use of anti-TLRl 0 antibody fragments.
  • Antibody fragments can be prepared by proteolytic hydrolysis of an antibody or by expression in E. coli of the DNA coding for the fragment.
  • Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies.
  • antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab') 2 .
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • Fv fragments comprise an association of V H and V L chains, which can be noncovalent (Inbar et al, Proc. Nat'lAcad. Sci. USA 69:2659 (1972)).
  • the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.
  • the Fv fragments comprise V H and V L chains that are connected by a peptide linker.
  • These single-chain antigen binding proteins are prepared by constructing a structural gene comprising DNA sequences encoding the V H and V domains which are connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell, such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
  • CDR peptides (“minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest.
  • Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (Larrick, et al, Methods: A Companion to Methods in Enymology 2:106 (1991); Courtenay-Luck, pp. 166-179 in, Monoclonal Antibodies Production, Engineering and Clinical Applications, Eds. Ritter et al, Cambridge University Press (1995); Ward, et al, pp. 137-185 in, Monoclonal Antibodies Principles and Applications, Eds. Birch et al, Wiley-Liss, Inc. (1995)).
  • the present invention further provides the above- described antibodies in detectably labeled form.
  • Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, etc.) fluorescent labels (such as FlTC or rhodamine, etc.), paramagnetic atoms, etc. Procedures for accomplishing such labeling have been previously disclosed (Stemberger, et al, J. Histochem. Cytochem. 18:315 (1970); Bayer, et al, Meth. Enzym. 62:308 (1979); Engval, et al, Immunol. 109:129 (1972); Goding, J. Immunol Meth. 13:215 (1976)).
  • affinity labels such as biotin, avidin, etc.
  • enzymatic labels such as horseradish peroxidase, alkaline phosphatase, etc.
  • fluorescent labels such as FlTC or rhodamine, etc.
  • the labeled antibodies can be used for in vitro, in vivo, and in situ assays to identify cells or tissues in which TLR10 is expressed. Furthermore, the labeled antibodies can be used to identify the presence of secreted TLR10 in a biological sample, such as a blood, urine, and saliva samples.
  • a biological sample such as a blood, urine, and saliva samples.
  • the present invention contemplates the use of "naked" anti-TLRl 0 antibodies, as well as the use of immunoconjugates.
  • Immnunoconjugates can be prepared by indirectly conjugating a therapeutic agent such as a cytotoxic agent to an antibody component.
  • Toxic moieties include, for example, plant toxins, such as abrin, ricin, modeccin, viscumin, pokeweed anti- viral protein, saporin, gelonin, momoridin, trichosanthin, barley toxin; bacterial toxins, such as Diptheria toxin, Pseudomonas endotoxin and exotoxin, Staphylococcal entero toxin A; fungal toxins, such as ⁇ -sarcin, restrictocin; cytotoxic
  • RNases such as extracellular pancreatic RNases; DNase I (Pastan, et al, Cell 47:641 (1986); Goldenberg, Cancer Journal far Clinicians 44:43 (1994)), calicheamicin, and radioisotopes, such as 32 P, 67 Cu, 77 As, 105 Rh, 109 Pd, m Ag, 121 Sn, 131 1, 166 Ho, 177 Lu, 186 Re, 188 Re, 194 Ir, 199 Au (midge, T.M. & Brock, S., CurrPharm. Design 6: 1399 (2000)). In humans, clinical trials are underway utilizing a yttrium-90 conjugated anti-CD20 antibody for B cell lymphomas ⁇ Cancer Chemother Pharmacol 48(Suppl 1):S91-S95 (2001)).
  • the general method involves reacting an antibody component having an oxidized carbohydrate portion with a carrier polymer that has at least one free amine function and that is loaded with a plurality of drug, toxin, chelator, boron addends, or other therapeutic agent. This reaction results in an initial Schiff base (imine) linkage, which can be stabilized by reduction to a secondary amine to form the final conjugate.
  • the carrier polymer is preferably an aminodextran or polypeptide of at least 50 amino acid residues, although other substantially equivalent polymer carriers can also be used.
  • the final immunoconjugate is soluble in an aqueous solution, such as mammalian serum, for ease of administration and effective targeting for use in therapy.
  • solubilizing functions on the carrier polymer will enhance the serum solubility of the final immunoconjugate.
  • an aminodextran will be preferred.
  • the process for preparing an inmmunoconjugate with an aminodextran carrier typically begins with a dextran polymer, advantageously a dextran of average molecular weight of about 10,000-100,000.
  • the dextran is reacted with an oxidizing agent to affect a controlled oxidation of a portion of its carbohydrate rings to generate aldehyde groups.
  • the oxidation is conveniently effected with glycolytic chemical reagents such as NaIO , according to conventional procedures.
  • the oxidized dextran is then reacted with a polyamine, preferably a diamine, and more preferably, a mono- or polyhydroxy diamine.
  • Suitable amines include ethylene diamine, propylene diamine, or other like polymethylene diamines, diethylene triamine or like polyamines, l,3-diamino-2-hydroxypropane, or other like hydroxylated diamines or polyamines, and the like.
  • An excess of the amine relative to the aldehyde groups of the dextran is used to ensure substantially complete conversion of the aldehyde functions to Schiff base groups.
  • a reducing agent such as NaBH , NaBH CN or the like, is used to effect reductive stabilization of the resultant Schiff base intermediate.
  • the resultant adduct can be purified by passage through a conventional sizing column or ultrafiltration membrane to remove cross-linked dextrans.
  • a dextran to introduce amine functions can also be used, e.g., reaction with cyanogen bromide, followed by reaction with a diamine.
  • the amninodextran is then reacted with a derivative of the particular drug, toxin, chelator, immunomodulator, boron addend, or other therapeutic agent to be loaded, in an activated form, preferably, a carboxyl-activated derivative, prepared by conventional means, e.g., using dicyclohexylcarbodiimide (DCC) or a water soluble variant thereof, to form an intermediate adduct.
  • DCC dicyclohexylcarbodiimide
  • polypeptide toxins such as pokeweed antiviral protein or ricin A-chain, and the like, can be coupled to aminodextran by glutaraldehyde condensation or by reaction of activated carboxyl groups on the protein with amines on the aminodextran.
  • Chelators for radiometals or magnetic resonance enhancers are well-known in the art.
  • Typical are derivatives of ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTP A).
  • EDTA ethylenediaminetetraacetic acid
  • DTP A diethylenetriaminepentaacetic acid
  • chelators typically have groups on the side chain by which the chelator can be attached to a carrier. Such groups include, e.g., benzylisothiocyanate, by which the DTPA or EDTA can be coupled to the amine group of a carrier.
  • carboxyl groups or amine groups on a chelator can be coupled to a carrier by activation or prior derivatization and then coupling, all by well-known means.
  • Boron addends, such as carboranes can be attached to antibody components by conventional methods.
  • carboranes can be prepared with carboxyl functions on pendant side chains, as is well known in the art. Attachment of such carboranes to a carrier, e.g., aminodextran, can be achieved by activation of the carboxyl groups of the carboranes and condensation with amines on the carrier to produce an intermediate conjugate. Such intermediate conjugates are then attached to antibody components to produce therapeutically useful immunoconjugates, as described below.
  • a carrier e.g., aminodextran
  • a polypeptide carrier can be used instead of aminodextran, but the polypeptide carrier should have at least 50 amino acid residues in the chain, preferably 100-5000 amino acid residues. At least some of the amino acids should be lysine residues or glutamate or aspartate residues. The pendant amines of lysine residues and pendant carboxylates of glutamine and aspartate are convenient for attaching a drug, toxin, immunomodulator, chelator, boron addend or other therapeutic agent.
  • suitable polypeptide carriers include polylysine, polyglutamic acid, polyaspartic acid, co-polymers thereof, and mixed polymers of these amino acids and others, e.g., serines, to confer desirable solubility properties on the resultant loaded carrier and immunoconjugate.
  • Conjugation of the intermediate conjugate with the antibody component is effected by oxidizing the carbohydrate portion of the antibody component and reacting the resulting aldehyde (and ketone) carbonyls with amine groups remaining on the carrier after loading with a drug, toxin, chelator, immunomodulator, boron addend, or other therapeutic agent.
  • an intermediate conjugate can be attached to an oxidized antibody component via amine groups that have been introduced in the intermediate conjugate after loading with the therapeutic agent. Oxidation is conveniently effected either chemically, e.g., with NaIO or other glycolytic reagent, or enzymatically, e.g., with neuraminidase and galactose oxidase.
  • an aminodextran carrier not all of the amines of the aminodextran are typically used for loading a therapeutic agent.
  • the remaining amines of aminodextran condense with the oxidized antibody component to form Schiff base adducts, which are then reductively stabilized, normally with a borohydride reducing agent.
  • Analogous procedures are used to produce other immunoconjugates according to the invention.
  • Loaded polypeptide carriers preferably have free lysine residues remaining for condensation with the oxidized carbohydrate portion of an antibody component.
  • Carboxyls on the polypeptide carrier can, if necessary, be converted to amines by, e.g., activation with DCC and reaction with an excess of a diamine.
  • the final immunoconjugate is purified using conventional techniques, such as sizing chromatography on Sephacryl S-300 or affinity chromatography using one or more TLRIO epitopes.
  • immunoconjugates can be prepared by directly conjugating an antibody component with a therapeutic agent.
  • the general procedure is analogous to the indirect method of conjugation except that a therapeutic agent is directly attached to an oxidized antibody component. It will be appreciated that other therapeutic agents can be substituted for the chelators described herein. Those of skill in the art will be able to devise conjugation schemes without undue experimentation.
  • a therapeutic agent can be attached at the hinge region of a reduced antibody component via disulfide bond formation.
  • the tetanus toxoid peptides can be constructed with a single cysteine residue that is used to attach the peptide to an antibody component.
  • such peptides can be attached to the antibody component using a heterobifunctional cross-linker, such as N-succinyl 3-(2- pyridyldithio)proprionate (SPDP) (Yu, et al, Int. J. Cancer 56:244 (1994)).
  • SPDP N-succinyl 3-(2- pyridyldithio)proprionate
  • carbohydrate moieties in the Fc region of an antibody can be used to conjugate a therapeutic agent.
  • the Fc region may be absent if an antibody fragment is used as the antibody component of the immunoconjugate. Nevertheless, it is possible to introduce a carbohydrate moiety into the light chain variable region of an antibody or antibody fragment (Leung, et al leverage J. Immunol 154:5919-5926 (1995); U.S. Pat.
  • the engineered carbohydrate moiety is then used to attach a therapeutic agent.
  • the carbohydrate moiety can be used to attach polyethyleneglycol in order to extend the half-life of an intact antibody, or antigen-binding fragment thereof, in blood, lymph, or other extracellular fluids.
  • the present invention contemplates the use of fusion proteins comprising one or more anti-TLRl 0 antibody moieties and an immunomodulator or toxin moiety.
  • Methods of making antibody fusion proteins have been previously described (U.S. Patent No. 6,306,393).
  • Antibody fusion proteins comprising an interleukin-2 moiety have also been previously disclosed (Boleti, et al, Ann. Oncol. 6:945 (1995), Nicolet, et al, Cancer Gene Tlier. 2:161 (1995), Becker, et al, Proc. Nat'lAcad. Sci. USA 93:7826 (1996), Hanlc, et al, Clin. Cancer Res.
  • Antibody-toxin fusion proteins containing a diphtheria toxin moiety have been described (Kreitman, et al, Leukemia 7:553 (1993), NichoUs, et al, J. Biol Chem. 268:5302 (1993), Thompson, et al, J. Biol Chem.
  • BIOT005 BIOT005; Dohlsten, et al, Proc. Nat'lAcad. Sci. USA 91:8945 (1994)).
  • Fab FRAGMENTS AND SINGLE CHAIN ANTIBODIES According to the invention, techniques can be adapted for the production of single-chain antibodies specific to TLR10 (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F a expression libraries ⁇ see e.g., Huse, et al, Science 246:1275-1281 (1989)) to allow rapid and effective identification of monoclonal F a b fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof.
  • Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F (ab')2 fragment produced by pepsin digestion of an antibody molecule; (ii) an F a fragment generated by reducing the disulfide bridges of an F (ab ' )2 fragment; (iii) an F a fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v fragments.
  • Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens.
  • one of the binding specificities is for an antigenic protein of the invention.
  • the second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.
  • bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al, 1991 EMBOJ., 10, 3655-3659.
  • Antibody variable domains with the desired binding specificities can be fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light-chain binding present in at least one of the fusions.
  • CHI first heavy-chain constant region
  • the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture.
  • the preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
  • one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan).
  • Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
  • Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g. F(ab') bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al, Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
  • TAB thionitrobenzoate
  • One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies.
  • Shalaby et al, J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule.
  • Fab' fragment was separately secreted fromE. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody.
  • the bispecific antibody thus formed was able to bind to cells overexpressing the ⁇ rbB2 receptor and normal human T cells, as well as trigger the lyric activity of human cytotoxic lymphocytes against human breast tumor targets.
  • bispecific antibodies have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
  • the fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and VH domains of another fragment, thereby forming two antigen-binding sites.
  • VH heavy-chain variable domain
  • VL light-chain variable domain
  • Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al, J. Immunol 152:5368 (1994).
  • Antibodies with more than two valencies are contemplated.
  • trispecific antibodies can be prepared. Tutt et al, J. Immunol. 147:60 (1991).
  • Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention.
  • an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as FC7RI (CD64), FC7RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen.
  • a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as FC7RI (CD64), FC7RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen.
  • Fc R Fc receptor
  • Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPT A, DOT A, or TETA.
  • a radionuclide chelator such as EOTUBE, DPT A, DOT A, or TETA.
  • Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).
  • TF tissue factor
  • Heteroconjugate antibodies are also within the scope of the present invention.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089).
  • the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
  • cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated can have improved internalization capability and/or increased complement- mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al, J. Exp Med., 176:1191-1195 (1992) and Shopes, J Immunol, 148:2918-2922 (1992).
  • Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobiiunctional cross-linkers as described in Wolff et al Cancer Research, 53:2560- 2565 (1993).
  • an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al,
  • TLRIO PEPTIDES The TLRIO peptide itself may be used to target toxins or radioisotopes to tumor cells in vivo.
  • TLRIO may be a homophihc adliesion protein which will bind to itself.
  • the extracellular domain of TLRIO, or a fragment of this domain may be able to bind to TLRIO expressed on tumor cells.
  • This peptide fragment then may be used as a means to deliver cytotoxic agents to TLRIO bearing tumor cells. Much like an antibody, these fragments may specifically target cells expressing this antigen. Targeted delivery of these cytotoxic agents to the tumor cells would result in cell death and suppression of tumor growth.
  • TLR10 binding receptor Cell surface molecules that bind TLRl 0 polypeptides, herein denoted TLr 10 binding receptors, may be useful for TLR10 targeting therapy.
  • Extracellular fragments of a TLR10 receptor may be used to modulate immune cells expressing the protein. On cells bearing a TLR10 binding receptor (such as neutrophils, NK cells, T cells, B cells and myeloid cells) this may result in stimulating the release of cytokines (such as interferon gamma for example) that may enhance or suppress the immune system.
  • cytokines such as interferon gamma for example
  • binding of these fragments to cells bearing a TLR10 binding receptor may result in the activation of these cells and also may stimulate proliferation.
  • Some fragments may bind to an intact TLR10 binding receptor and block activation signals and cytokine release by immune cells. These fragments would then have an immunosuppressive effect. Fragments that activate and stimulate the immune system may have anti-tumor properties. These fragments may stimulate an immunological response that can result in immune mediated tumor cell killing. The same fragments may result in stimulating the immune system to mount an enhance response to foreign invaders such as viruses and bacteria.
  • Fragments that suppress the immune response may be useful in treating lyrnphoproliferative disorders, autoimmune disease, graft-vs-host disease, and inflammatory disorders such as
  • TLRIO protein maybe useful for identification of therapeutic molecules that function to specifically bind to or even inhibit the activity of TLRIO. Synthetic and naturally occurring products can be screened in a number of ways deemed routine to those of skill in the art.
  • Random peptide libraries are displayed on phage (phage display) or on bacteria, such as on
  • random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or a polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
  • a known target which can be a protein or a polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.
  • diversity libraries such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically bind to TLRIO polypeptides.
  • Many libraries are known in the art that can be used, i.e. chemically synthesized libraries, recombinant ⁇ i.e. phage display libraries), and in vitro translation-based libraries. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al, U.S.
  • phage display libraries are described in Scott and Smith, Science 249:386-390 (1990); Devlin et al, Science 249:404-406 (1990); Christian et al, J. Mol Biol. 227:711-718 (1992); Lenstra, J. Immunol Meth. 152:149-157 (1992); Kay et al, Gene 128:59-65 (1993); PCT Publication No. WO 94/18318, all of which are herein incorporated by reference in their entirety.
  • non-peptide libraries a benzodiazepine library (see for example, Bunin et al, Proc. Natl. Acad. Sci USA 91:4708-4712 (1994), herein incorporated by reference in its entirety) can be adapted for use.
  • Peptoid libraries (Simon et al, Proc. Natl. Acad. Sci USA 89:9367-9371 (1992), herein incorporated by reference in its entirety) can also be used.
  • Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. ⁇ Proc. Natl. Acad. Sci.
  • Screening the libraries can be accomplished by any of a variety of commonly known methods. See, for example, the following references which disclose screening of peptide libraries: Parmley and Smith, Adv. Exp. Med. Biol. 251:215-218 (1989); Scott and Smith, Science 249:386-390 (1990); Fowlkes et al, Biotechniques 13:422-427 (1992); Oldenburg et al, Proc. Natl. Acad. Sci.
  • screening can be carried out by contacting the library members with a TLR10 protein (or nucleic acid or derivative) immobilized on a solid phase and harvesting those library members that bind to the protein (or nucleic acid or derivative).
  • TLR10 protein or nucleic acid or derivative
  • Examples of such screening methods termed “panning” techniques are described by way of example in Parmley and Smith, Gene 73:305-318 (1988); Fowlkes et al, Biotechniques 13:422-427 (1992); PCT Publication No. WO 94/18318, all of which are herein incorporated by reference in their entirety, and in references cited hereinabove.
  • the two-hybrid system for selecting interacting protein in yeast can be used to identify molecules that specifically bind to TLRIO or a TLRIO derivative.
  • binding polypeptides or small molecules which interact with TLRIO polypeptides can be used for tagging or targeting cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like.
  • binding polypeptides or small molecules can also be used in analytical methods such as for screening expression libraries and neutralizing activity, i.e., for blocking interaction between ligand and receptor, or viral binding to a receptor.
  • the binding polypeptides or small molecules can also be used for diagnostic assays for determining circulating levels of TLRIO polypeptides of the invention; for detecting or quantitating soluble TLRIO polypeptides as marker of underlying pathology or disease.
  • binding polypeptides or small molecules can also act as TLRIO "antagonists" to block TLRIO binding and signal transduction in vitro and in vivo. These TLRIO binding polypeptides or small molecules would be useful for inhibiting TLRIO activity or protein binding.
  • Binding polypeptides can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. Binding peptides can also be fused to other polypeptides, for example an immunoglobulin constant chain or portions thereof, to enhance their half-life, and can be made multivalent (through, e.g. branched or repeating units) to increase binding affinity for TLR10.
  • binding polypeptides of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance). More specifically, binding polypeptides or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti- complementary molecule.
  • Suitable detectable molecules may be directly or indirectly attached to the binding polypeptide, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like.
  • Suitable cytotoxic molecules may be directly or indirectly attached to the binding polypeptide, and include bacterial or plant toxins (for instance, diphtheria toxin, Pseudomonas exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188, or yttrium-90 (either directly attached to the binding polypeptide, or indirectly attached through a means of a chelating moiety, for instance).
  • Binding polypeptides may also be conjugated to cytotoxic drugs, such as adriamycin.
  • cytotoxic drugs such as adriamycin.
  • the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anticomplementary pair, where the other member is bound to the binding polypeptide.
  • biotin/streptavidin is an exemplary complementary/anticomplementarypair.
  • binding polypeptide-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues).
  • a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule, or a complementary molecule to a cell or tissue type of interest.
  • the domain only fusion protein includes a complementary molecule
  • the anti- complementary molecule can be conjugated to a detectable or cytotoxic molecule.
  • Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/cytotoxic molecule conjugates.
  • the present invention provides reagents and methods useful for treating diseases and conditions wherein cells associated with the disease or disorder express TLRIO.
  • diseases can include cancers, and other hyperproliferative conditions, such as hyperplasia, psoriasis, contact dermatitis, immunological disorders, and infertility. Whether the cells associated with a disease or condition express TLRIO can be detennined using the diagnostic methods described herein.
  • TLRIO mRNA and protein expression levels are made to determine if the patient will be responsive to TLRIO targeting therapy.
  • Methods for detecting and quantifying the expression of TLRIO mRNA or protein use standard nucleic acid and protein detection and quantitation techniques that are well known in the art and are described in Sambrook, et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989) or Ausubel, et al, Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY (1989), both of which are incorporated herein by reference in their entirety.
  • Standard methods for the detection and quantification of TLRIO mRNA include in situ hybridization using labeled TLRIO riboprobes (Gemou-Engesaeth, et al, Pediatrics 109: E24-E32 (2002)), Northern blot and related techniques using TLR10 polynucleotide probes (Kunzli, et al, Cancer 94: 228 (2002)), RT-PCR analysis using TLRl 0-specific primers (Angchaiskisiri, et al, Blood 99: 130 (2002)), and other amplification detection methods, such as branched chain DNA solution hybridization assay (Jardi, et al, J. Viral Hepat.
  • Standard methods for the detection and quantification of TLRl 0 protein include western blot analysis (Sambrook, et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989), Ausubel, et al, Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY (1989)), immunocytochemistry (Racila, et al, Proc. Natl. Acad. Sci.
  • ELISA enzyme-linked immunosorbant assay
  • RIA radioimmunoassay
  • EIA specific enzyme immunoassay
  • Peripheral blood cells can also be analyzed for TLR10 expression using flow cytometry using, for example, immunomagnetic beads specific for TLR10 (Racila, et al, Proc. Natl. Acad. Sci.
  • the disease or disorder is a cancer.
  • the cancers treatable by methods of the present invention preferably occur in mammals. Mammals include, for example, humans and other primates, as well as pet or companion animals such as dogs and cats, laboratory animals such as rats, mice and rabbits, and farm animals such as horses, pigs, sheep, and cattle.
  • Tumors or neoplasms include growths of tissue cells in which the multiplication of the cells is uncontrolled and progressive. Some such growths are benign, but others are termed “malignant” and may lead to death of the organism. Malignant neoplasms or “cancers” are distinguished from benign growths in that, in addition to exhibiting aggressive cellular proliferation, they may invade surrounding tissues and metastasize. Moreover, malignant neoplasms are characterized in that they show a greater loss of differentiation
  • Neoplasms treatable by the present invention also include solid phase tumors/malignancies, i.e., carcinomas, locally advanced tumors and human soft tissue sarcomas.
  • Carcinomas include those malignant neoplasms derived from epithelial cells that infiltrate (invade) the surrounding tissues and give rise to metastastic cancers, including lymphatic metastases.
  • Adenocarcinomas are carcinomas derived from glandular tissue, or which form recognizable glandular structures.
  • Another broad category or cancers includes sarcomas, which are tumors whose cells are embedded in a fibrillar or homogeneous substance like embryonic connective tissue. As seen in Table 4, TLRIO is expressed in breast, colon, prostate, and squamous cell carcinoma.
  • TLRIO tumor necrosis virus
  • the invention also enables treatment of cancers of the myeloid or lymphoid systems, including leukemias, lymphomas and other cancers that typically do not present as a tumor mass, but are distributed in the vascular or lymphoreticular systems.
  • the type of cancer or tumor cells that may be amenable to treatment according to the invention include, for example, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, cutaneous T-cell lymphoma, hairy cell leukemia, acute myeloid leukemia, erythroleukemia, chronic myeloid (granulocytic) leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer, polyps associated with colorectal neoplasms, pancreatic cancer and gallbladder cancer, cancer of the adrenal cortex, ACTH-producing tumor, bladder cancer, brain cancer including intrinsic brain tumors, neuroblastomas, astrocytic brain tumors, gliomas, and metastatic tumor cell invasion of the central nervous system, Ewing's sarcoma, head and neck cancer
  • the invention is particularly illustrated herein in reference to treatment of certain types of experimentally defined cancers.
  • standard state-of- the-art in vitro and in vivo models have been used. These methods can be used to identify agents that can be expected to be efficacious in in vivo treatment regimens.
  • the method of the invention is not limited to the treatment of these tumor types, but extends to any cancer derived from any organ system.
  • TLR9 and TLRIO are highly expressed in B-cell related disorders. Leukemias can result from uncontrolled B cell proliferation initially within the bone marrow before disseminating to the peripheral blood, spleen, lymph nodes and finally to other tissues.
  • TLR9 or TLRIO is used in treating B cell malignancies, leukemias, lymphomas and myelomas including but not limited to multiple myeloma, Burkitt's lymphoma, cutaneous B cell lymphoma, primary foUicular cutaneous B cell lymphoma, B lineage acute lymphoblastic leukemia (ALL), B cell non-Hodgkin's lymphoma (NHL), B cell chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, hairy cell leukemia (HCL), acute myelogenous leukemia, acute myelomonocytic leukemia, chronic myelogenous leukemia, lymphosarcoma cell leukemia, B cell large cell lymphoma, malignant lymphoma, splenic marginal zone lymphoma, diffuse
  • TLR10 has also been demonstrated in Examples 1-2 in myeloid leukemia cell lines and tissue, T cell leukemia cell lines and T cell lymphoma tissues and may be treated with TLR10 antibodies.
  • Other diseases that may be treated by the methods of the present invention include multicentric Castleman's disease, primary amyloidosis, Franklin's disease, Seligmann's disease, primary effusion lymphoma, post-transplant lymphoproliferative disease (PTLD) [associated with EBV infection.], paraneoplastic pemphigus, chronic lymphoproliferative disorders, X-linked lymphoproliferative syndrome (XLP), acquired angioedema, angioimmunoblastic lymphadenopafhy with dysproteinemia, Herman's syndrome, post-splenectomy syndrome, congenital dyserythropoietic anemia type
  • LAHS lymphoma-associated hemophagocytic syndrome
  • Kikuchi's disease necrotizing ulcerative stomatitis
  • Kikuchi's disease lymphomatoid granulomatosis
  • Richter's syndrome polycythemic vera (PV)
  • Gaucher's disease Gougerot-Sjogren syndrome
  • Kaposi's sarcoma cerebral lymphoplasmocytic proliferation (Bind and Neel syndrome)
  • X-linked lymphoproliferative disorders pathogen associated disorders such as mononucleosis
  • Epstein Barr Virus lymphoplasma cellular disorders, post-transplantational plasma cell dyscrasias, and Good's syndrome.
  • Autoimmune diseases can be associated with hyperactive B cell activity that results in autoantibody production, hihibition of the development of autoantibody-producing cells or proliferation of such cells maybe therapeutically effective in decreasing the levels of autoantibodies in autoimmune diseases including but not limited to systemic lupus erythematosus, Crohn's Disease, graft- verses-host disease, Graves' disease, myasthenia gravis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, asthma, cryoglubulinemia, primary biliary sclerosis, pernicious anemia, Waldenstrom macroglobulinemia, hyperviscosity syndrome, macroglobulinemia, cold agglutinin disease, monoclonal gammopathy of undetermined origin, anetoderma and POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M component, skin changes), connective tissue disease, multiple sclerosis, cystic fibrosis, rheumatoid arthritis, autoimmune pulmonary inflammation
  • TLR10 expression As shown in Table 5, JJHC analysis showed TLR10 expression on tissues from the following autoimmune disorders: systemic lupus erythematosus, Hasimoto thyroiditis, Sj ⁇ rgen's syndrome, and pericarditis lupus; thus targeting TLR10 may be useful therapies for these and other autoimmune disorders.
  • TLR10 may also be useful in the treatment of allergic reactions and conditions e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens- Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis, allergic gastroenteropathy, inflammatory bowel disorder
  • allergic reactions and conditions e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis
  • IBD IBD
  • contact allergies such as asthma (particularly allergic asthma), or other respiratory problems.
  • Targeting TLRIO may also be useful in the management or prevention of transplant rejection in patients in need of transplants such as stem cells, tissue or organ transplant.
  • one aspect of the invention may find therapeutic utility in various diseases (such as those usually treated with transplantation, including without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria) as wells in repopulating the stem cell compartment post irridiation/chemotherapy, either in vivo or ex vivo ⁇ i.e. in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous) as normal cells or genetically manipulated for gene therapy.
  • TLRIO is expressed in rejected heart, liver and kidney tissue after transplantation as opposed to normal tissue.
  • targeting of TLRIO may be useful to prevent and/or reduce tissue rejection after transplantation.
  • Targeting of TLRIO may also be possible to modulate immune responses, in a number of ways.
  • Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response.
  • Down regulating or preventing one or more antigen functions including without limitation B lymphocyte antigen functions (such as, for example, TLR10)), e.g., modulating or preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD).
  • GVHD graft-versus-host disease
  • blockage of T cell function should result in reduced tissue destruction in tissue transplantation.
  • rejection of the transplant is initiated through its recognition as foreign by T cells ⁇ i.e.
  • cytotoxic T lymphocytes followed by an immune reaction that destroys the transplant.
  • the administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant.
  • a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject.
  • Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents.
  • the efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.
  • appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al, Science 257:789-792 (1992) and Turka et al, Proc. Natl
  • TLR10 may also be useful in the treatment of chronic inflammation.
  • TLR10 is highly expressed in neutrophils. Leukocytes, including neutrophils, are recruited to sites of infection or injury and are subsequently cleared at the end of the inflammatory response. However, in situations of chronic inflammation, removal of such neutrophils is impaired or inhibited; therefore, destruction of these neutrophils by means of TLrlO targeting can be used in the management of chronic inflammation.
  • Conditions that may benefit from such therapy include, but are not limited to, inflammatory disorders, autoimmune diseases, asthma, chronic pancreatitis, allergic dermatitis, idiopathic pulmonary fibrosis, upper and lower respiratory infection, acute pulmonary inflammation, wound healing, graft vs. host disease, chronic obstructive pulmonary disease, arthritis, periodontitis, and disorders relating to oxidative stress, including hypertension pathogenesis and athlerosclerosis.
  • the anti-TLRl 0 monoclonal antibodies used in the practice of a method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method.
  • Suitable carriers include any material which when combined with the anti-TLRl 0 antibodies retain the anti-tumor function of the antibody and are nonreactive with the subject's immune systems. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like.
  • the anti-TLRl 0 antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site.
  • Potentially effective routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like.
  • the preferred route of administration is by intravenous injection.
  • a preferred formulation for intravenous injection comprises anti-TLRlO mAbs in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile sodium chloride for
  • the anti-TLRlO mAb preparation may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.
  • Treatment will generally involve the repeated administration of the anti-TLRl 0 antibody preparation via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight; however other exemplary doses in the range of 0.01 mg/kg to about 100 mg/kg are also contemplated. Doses in the range of 10-500 mg mAb per week may be effective and well tolerated.
  • Rituximab (Rituxan®), a chimeric CD20 antibody used to treat B-cell lymphoma, non- Hodgkin's lymphoma, and relapsed indolent lymphoma, is typically administered at 375 mg/m 2 by IV infusion once a week for 4 to 8 doses.
  • Rituxan® a humanized monoclonal antibody used to treat HER2 (human epidermal growth factor 2)-positive metastatic breast cancer (Slamon, et al, Mol Cell Biol.
  • an initial loading dose of approximately 4 mg/kg patient body weight IV followed by weekly doses of about 2 mg/kg IV of the anti-TLRl 0 mAb preparation may represent an acceptable dosing regimen (Slamon, et al, N. Engl. J. Med. 344: 783(2001)).
  • the initial loading dose is administered as a 90 minute or longer infusion.
  • the periodic maintenance dose may be adininistered as a 30 minute or longer infusion, provided the initial dose was well tolerated.
  • various factors will influence the ideal dose regimen in a particular case.
  • Such factors may include, for example, the binding affinity and half life of the mAb or mAbs used, the degree of TLR10 overexpression in the patient, the extent of circulating shed TLR10 antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic agents used in combination with the treatment method of the invention.
  • Treatment can also involve anti-TLRl 0 antibodies conjugated to radioisotopes.
  • anti-CEA radiolabeled-anticarcinoembryonic antigen
  • dendritic cells transfected with mRNA encoding TLR10 can be used as a vaccine to stimulate T-cell mediated anti-tumor responses.
  • Studies with dendritic cells transfected with prostate-specific antigen mRNA suggest 3 cycles of intravenous administration of 1 x 10 7 - 5x 10 7 cells for 2-6 weeks concomitant with an intradermal injection of 10 7 cells may provide a suitable dosage regimen (Heiser, et al, J. Clin. Invest. 109:409-417 (2002); Hadzantonis and O'Neill, Cancer Biother. Radiopharm. 1:11-22 (1999)).
  • Other exemplary doses of between 1x10 5 to lxlO 9 or lxlO 6 to lxlO 8 cells are also contemplated.
  • Patent application WO200188200-A2 teaches the use of naked DNA vaccines by particle bombardment technique where Ly-9 (a member of the immunoglobulin (Ig) superfamily) DNA-coated microprojectiles at high velocity are used to pierce cell membranes and enter cells without killing the cells.
  • Ly-9 a member of the immunoglobulin (Ig) superfamily
  • Administration of naked DNA by direct injection into the skin and muscle is not associated with limitations encountered using viral vectors, such as the development of adverse immune reactions and risk of insertional mutagenesis (Hengge, et al, J. Invest. Dermatol 116:979 (2001)).
  • HIV-1 DNA vaccine dose-escalating studies indicate administration of 30-300 ⁇ g/dose as a suitable therapy (Weber, et al, Eur. J. Clin. Microbiol In/ect. Dis. 20: 800). Naked DNA injected intracerebrally into the mouse brain was shown to provide expression of a reporter protein, wherein expression was dose-dependent and maximal for 150 ⁇ g DNA injected (Schwartz, et al, Gene Ther.
  • patients should be evaluated for the level of circulating shed TLR10 antigen in serum in order to assist in the determination of the most effective dosing regimen and related factors. Such evaluations may also be used for monitoring purposes throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters.
  • compositions for targeting TLRlO-expressing cells are within the scope of the present invention.
  • Pharmaceutical compositions comprising antibodies are described in detail in, for example, US Patent No. 6,171,586, to Lam et al, issued January 9, 2001.
  • Such compositions comprise a therapeutically or prophylactically effective amount an antibody, or a fragment, variant, derivative or fusion thereof as described herein, in admixture with a pharmaceutically acceptable agent.
  • the TLR10 targeting agent will be sufficiently purified for administration to an animal.
  • the pharmaceutical composition may contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition.
  • formulation materials for modifying, maintaining or preserving for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition.
  • Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, other organic acids); bulking agents (such as mannitol or glycine), chelating agents [such as ethylenediamine tetraacetic acid (EDTA)]; complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (such as glucose, mamiose, or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring; flavoring and diluting agents; emulsifying
  • compositions will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format, and desired dosage. See, for example, Remington 's Pharmaceutical Sciences, supra. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the TLR10 targeting agent.
  • the primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature.
  • a suitable vehicle or carrier may be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration.
  • Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles.
  • Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which may further include sorbitol or a suitable substitute therefor.
  • TLR10 targeting agent compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents ⁇ Remington's Pharmaceutical Sciences, supra) in the fonn of a lyophilized cake or an aqueous solution. Further, the binding agent product may be formulated as a lyophilizate using appropriate excipients such as sucrose. The pharmaceutical compositions can be selected for parenteral delivery.
  • compositions may be selected for inhalation or for delivery through the digestive tract, such as orally.
  • the preparation of such pharmaceutically acceptable compositions is within the skill of the art.
  • the formulation components are present in concentrations that are acceptable to the site of administration.
  • buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8.
  • the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the TLRIO targeting agent in a pharmaceutically acceptable vehicle.
  • a particularly suitable vehicle for parenteral injection is sterile distilled water in which a TLRIO targeting agent is formulated as a sterile, isotonic solution, properly preserved.
  • a TLRIO targeting agent is formulated as a sterile, isotonic solution, properly preserved.
  • another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (polylactic acid, polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which may then be delivered via a depot injection.
  • Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation.
  • Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.
  • compositions suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes.
  • Non-lipid polycationic amino polymers may also be used for delivery.
  • the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.
  • a phannaceutical composition may be fonnulated for inhalation.
  • a TLR10 targeting agent may be formulated as a dry powder for inhalation.
  • Polypeptide or nucleic acid molecule inhalation solutions may also be formulated with a propellant for aerosol delivery.
  • solutions may be nebulized. Pulmonary administration is further described in PCT Application No.
  • PCT/US94/001875 which describes pulmonary delivery of chemically modified proteins.
  • TLRIO targeting agents that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules.
  • a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized.
  • Additional agents can be included to facilitate absorption of the binding agent molecule. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.
  • compositions for oral administration can also be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration.
  • Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores.
  • auxiliaries can be added, if desired.
  • Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen.
  • disintegrating or solubilizing agents may be added, such as the cross-linked polyvmyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.
  • Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
  • Pharmaceutical preparations that can be used orally also include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
  • Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers, hi soft capsules, the TLRIO targeting agent may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • suitable liquids such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • Another pharmaceutical composition may involve an effective quantity of TLRIO targeting agent in a mixture with non-toxic excipients that are suitable for the manufacture of tablets.
  • excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.
  • sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules.
  • Sustained release matrices may include polyesters, hydrogels, polylactides (U.S. Patent No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al, Biopolymers, 22:547-556 (1983)), poly (2-hydroxyethyl-methacrylate) (Langer et al, J Biomed Mater Res, 15:167-277, (1981)) and (Langer et al, Chem Tech, 12:98-105(1982)), ethylene vinyl acetate (Langer et al, supra) or poly-D (-)-3- hydroxybutyric acid (EP 133,988).
  • polyesters U.S. Patent No. 3,773,919, EP 58,481
  • copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et
  • Sustained-release compositions also include liposomes, which can be prepared by any of several methods known in the art. See e.g., Epstein, et al, Proc Natl Acad Sci (USA), 82:3688-3692 (1985); EP 36,676; EP 88,046; EP 143,949.
  • compositions to be used for in vivo administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method may be conducted either prior to or following lyophilization and reconstitution.
  • the composition for parenteral administration may be stored in lyophilized form or in solution, hi addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • the pharmaceutical composition may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized powder.
  • kits for producing a single-dose administration unit may each contain both a first container having a dried TLRIO targeting agent and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes).
  • An effective amount of a pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives.
  • One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the TLR10 targeting agent is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.
  • a typical dosage may range from about 0.1 mg/kg to up to about 100 mg/kg or more, depending on the factors mentioned above.
  • the dosage may range from 0.1 mg/kg up to about 100 mg/kg; or 0.01 mg/kg to 1 g/kg; or 1 mg/kg up to about 100 mg/kg or 5 mg/kg up to about 100 mg/kg. In other embodiments, the dosage may range from 10 mCi to 100 mCi per dose for radioimmunotherapy, from about 1x10 to 5x10 cells or lxlO 5 to 1x10 9 cells or lxlO 6 to l lO 8 cells per injection or infusion, or from 30 ⁇ g to 300 ⁇ g naked DNA per dose or 1-1000 ⁇ g/dose or 10-500 ⁇ g/dose, depending on the factors listed above.
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs.
  • animal models such as mice, rats, rabbits, dogs, or pigs.
  • An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Dosage and administration are adjusted to provide sufficient levels of the active compound or to maintain the desired effect. Factors that may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.
  • the frequency of dosing will depend upon the pharmacokinetic parameters of the TLRIO targeting agent in the fonnulation used.
  • a composition is administered until a dosage is reached that achieves the desired effect.
  • the composition may therefore be administered as a single dose or as multiple doses (at the same or different concentrations/dosages) over time, or as a continuous infusion. Further refinement of the appropriate dosage is routinely made. Appropriate dosages may be ascertained through use of appropriate dose-response data.
  • the route of administration of the pharmaceutical composition is in accord with known methods, e.g. orally, through injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intra-arterial, intraportal, intralesional routes, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means, by sustained release systems or by implantation devices.
  • the compositions may be administered by bolus injection or continuously by infusion, or by implantation device.
  • the composition may be administered locally via implantation of a membrane, sponge, or another appropriate material on to which the TLR10 targeting agent has been absorbed or encapsulated.
  • the device may be implanted into any suitable tissue or organ, and delivery of the TLR10 targeting agent may be via diffusion, timed-release bolus, or continuous administration.
  • a TLRIO targeting agent can be delivered by implanting certain cells that have been genetically engineered to express and secrete the polypeptide.
  • Such cells may be animal or human cells, and may be autologous, heterologous, or xenogeneic.
  • the cells may be immortalized.
  • the cells may be encapsulated to avoid infiltration of surrounding tissues.
  • the encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.
  • TLRIO targeting agents of the invention can be utilized in combination with other therapeutic agents.
  • these other therapeutics include, for example radiation treatment, chemotherapeutic agents, as well as other growth factors.
  • anti-TLRl 0 antibody is used as a radiosensitizer.
  • the anti-TLRl 0 antibody is conjugated to a radiosensitizmg agent.
  • the tenn "radiosensitizer,” as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to be radiosensitized to electromagnetic radiation and/or to promote the treatment of diseases that are treatable with electromagnetic radiation.
  • Diseases that are treatable with electromagnetic radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells.
  • electromagnetic radiation and “radiation” as used herein include, but are not limited to, radiation having the wavelength of 10 "20 to 100 meters.
  • Preferred embodiments of the present invention employ the electromagnetic radiation of: ga ma- radiation (10 ⁇ 20 to 10 "13 m), X-ray radiation (10 "12 to 10 “9 m), ultraviolet light (10 nm to 400 mn), visible light (400 nm to 700 nm), infrared radiation (700 nm to 1.0 mm), and microwave radiation (1 mm to 30 cm).
  • Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of electromagnetic radiation. Many cancer treatment protocols currently employ radiosensitizers activated by the electromagnetic radiation of X-rays.
  • X-ray activated radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C,
  • Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent.
  • photodynamic radiosensitizers include the following, but are not limited to: hematopo ⁇ hyrin derivatives, Photofrin(r), benzoporphyrin derivatives, NPe6, tin etioporphyrin (SnET2), pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.
  • Chemotherapy treatment can employ anti-neoplastic agents including, for example, alkylating agents including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamme (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, c
  • Combination therapy with growth factors can include cytokines, lymphokines, growth factors, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, LL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, LL-12, IL-13, IL-14, IL-15, IL-16, IL- 17, LL-18, LFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, GM-CSF, thro bopoietin, stem cell factor, and erythropoietin.
  • compositions can include known angiopoietins, for example, vascular endothelial growth factor (VEGF).
  • Growth factors include angiogenin, bone morphogenic protein-1, bone morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone morphogenic protein-5, bone morphogenic protein-6, bone morphogenic protein-7, bone morphogenic protein-8, bone morphogenic protein-9, bone morphogenic protein- 10, bone morphogenic protein- 11 , bone morphogenic protein- 12, bone morphogenic protein-13, bone morphogenic protein-14, bone morphogenic protein-15, bone morphogenic protein receptor IA, bone morphogenic protein receptor IB, brain derived neurotrophic factor, ciliary neutrophic factor, cytokine-induced neutrophil chemotactic factor 1, cytokine-induced neutrophil chemotactic factor 2, endothelial cell growth factor, endothelin 1, epidermal growth factor, epithelial-derived neutrophil attractant, fibroblast growth factor 4, fibroblast growth
  • Determining the status of TLRIO expression patterns in an individual may be used to diagnose cancer, or other disorder characterized by TLRIO expression, and may provide prognostic information useful in defining appropriate therapeutic options.
  • the expression status of TLRl 0 may provide information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness.
  • the invention provides methods and assays for determining TLRIO expression status and diagnosing diseases that express TLRIO.
  • the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in TLRl 0 mRNA or protein expression in a test cell or tissue or fluid sample relative to expression levels in the corresponding normal cell or tissue.
  • the presence of TLRIO mRNA is evaluated in tissue samples of a lymphoma.
  • the presence of significant TLRIO expression may be useful to indicate whether the lymphoma is susceptible to TLRIO targeting therapy.
  • TLR10 expression status may be determined at the protein level rather than at the nucleic acid level.
  • such a method or assay would comprise determining the level of TLR10 expressed by cells in a test tissue sample and comparing the level so determined to the level of TLR10 expressed in a corresponding normal sample.
  • the presence of TLRIO is evaluated, for example, using immunohistochemical methods.
  • TLRIO antibodies capable of detecting TLRIO expression may be used in a variety of assay formats well known in the art for this purpose.
  • Peripheral blood may be conveniently assayed for the presence of cancer cells, including lymphomas and leukemias, using RT-PCR to detect TLRIO expression.
  • the presence of RT-PCR amplifiable TLRIO mRNA provides an indication of the presence of one of these types of cancer.
  • a sensitive assay for detecting and characterizing carcinoma cells in blood may be used (Racila, et al, Proc. Natl. Acad. Sci. USA 95: 4589-4594 (1998)).
  • This assay combines immunomagnetic enrichment with multiparameter flow cytometric and immunohistochemical analyses, and is highly sensitive for the detection of cancer cells in blood, reportedly capable of detecting one epithelial cell in 1 ml of peripheral blood.
  • a related aspect of the invention is directed to predicting susceptibility to developing cancer in an individual.
  • a method for predicting susceptibility to cancer comprises detecting TLRIO mRNA or protein in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of TLRl 0 mRNA expression present is proportional to the degree of susceptibility.
  • a method for gauging aggressiveness of a tumor comprises determining the level of TLR10 mRNA or protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of TLR10 mRNA or protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of TLR10 mRNA or protein expression in the tumor sample relative to the normal sample indicates the degree of aggressiveness.
  • Methods for detecting and quantifying the expression of TLR10 mRNA or protein are described herein and use standard nucleic acid and protein detection and quantification technologies well known in the art.
  • Standard methods for the detection and quantification of TLR10 mRNA include in situ hybridization using labeled TLR10 riboprobes (Gemou- Engesaeth, et al, Pediatrics, 109:E24-E32 (2002)), Northern blot and related techniques using TLRl 0 polynucleotide probes (Kunzli, et al, Cancer 94:228 (2002)) , RT-PCR analysis using primers specific for TLR10 (Angchaiskisiri, et al, Blood 99:130 (2002)), and other amplification type detection methods, such as, for example, branched DNA (Jardi, et al, J. Viral Hepat.
  • SISBA Sudura, et al, J. Clin. Microbiol 40:439-445 (2002)
  • microarray products of a variety of sorts such as oligos, cDNAs, and monoclonal antibodies.
  • real-time RT-PCR may be used to detect and quantify TLR10 mRNA expression (Simpson, et al, Molec. Vision 6:178-183
  • polyclonal or monoclonal antibodies specifically reactive with the wild-type TLR10 may be used in an immunohistochemical assay of biopsied tissue (Ristimaki, et al, Cancer Res. 62:632 (2002)).
  • TLR10 expression characterized by TLR10 expression
  • autoimmune diseases or inflammatory diseases any of the aforementioned diseases is also contemplated using the assays outlined in this section.
  • TLR10 antibodies and fragments thereof are useful in medical imaging of sites expressing TLR10, respectively. Such methods involve chemical attachment of a labeling or imaging agent, such as a radioisotope, which include 67 Cu, 90 Y, 125 1, 131 1, 186 Re, 188 Re, 211 At, and Bi, administration of the labeled antibody and fragment to a subject in a pharmaceutically acceptable carrier, and imaging the labeled antibody and fragment in vivo at the target site.
  • Radiolabelled anti-TLRl 0 antibodies or fragments thereof may be particularly useful in in vivo imaging of TLR10 expressing cancers, such as lymphomas or leukemias. Such antibodies may provide highly sensitive methods for detecting metastasis of TLRlO-expressing cancers.
  • TLR10 TLR10 mRNA expression was determined in various lymphoid and myeloid cell lines.
  • Poly-A messenger RNA was isolated from the cell lines listed in Table 1 and subjected to quantitative, real-time PCR analysis (Simpson et al, Molec. Vision 6:178-183 (2000)) to determine the relative copy number of TLR10 mRNA expressed per cell in each line.
  • Elongation factor 1 mRNA expression was used as a positive control and normalization factor in all samples.
  • TLR10 TLR10 was determined in various healthy and tumor tissues (Table 2).
  • Poly-A mRNA was isolated from the lymphoma and acute myeloid leukemia tissue samples obtained from the Cooperative Human Tissue Network (CHTN, National Cancer Institute). All other RNAs were purchased from Clontech (Palo Alto, CA), Ambion (Austin, TX), and Stratagene (La Jolla, CA).
  • Tissues 5348 and 5856 were B cell foUicular lymphomas and samples 22601 and 6879 were diffuse large B cell lymphoma samples. Lymphoma patient tissue samples were snap frozen immediately after surgical removal.
  • Poly-A mRNA was subjected to quantitative, real-time PCR analysis, as described in Example 1, to determine the relative expression of TLR10 mRNA in the sample. All assays were performed in duplicate with the resulting values averaged and expressed as "-" for samples with no detectable TLRIO mRNA in that sample to "+++” for samples with the highest mRNA copy number for TLRIO.
  • TLRIO TLRIO expression was determined in various leukocytic cells.
  • DNA encoding elongation factor 1 mRNA was used as a positive control and nonnalization factors in all samples. All assays were performed in duplicate with the resulting values averaged.
  • the y-axis shows the relative expression of TLR10 mRNA, wherein the lowest expression was set as equal to 1 and the rest of the values are expressed as relative to 1.
  • FIG. 1 shows that TLR10 mRNA is highly expressed in neutrophils as compared to other leukocytes and their precursors, indicating that targeting TLR10 may be useful as a therapeutic or as a diagnostic for neutrophil-related disorders, such as inflammatory disorders.
  • TLRl 0 antibodies see Table 3. Samples were prepared for immunohistochemical (IHC) analysis (Clinomics Biosciences, Inc., Pittsfield, MA) by fixing tissues in 10%) formalin embedding in paraffin, and sectioning using standard techniques. Sections were stained using the TLRIO-specific antibody followed by incubation with a secondary horse radish peroxidase (HRP)-conjugated antibody and visualized by the product of the HRP enzymatic reaction. Data as seen in Table 3 shows that TLR10 is highly expressed on cell surface of tumor tissues. No expression of TLR10 was observed on the cell surface of normal tissues; however a low level of TLR10 expression could be detected in tonsils.
  • IHC immunohistochemical
  • TLR10 expression was found in solid tumors from prostate, breast, colon, and squamous cell carcinoma (see Table 4). Based on this expression pattern, it is likely that other cancers of epithelial and squamous cell origin will also express TLR10. Table 3
  • TLRIO was overexpressed in systemic lupus erythematosus, Hasimoto thyroiditis, Sjorgen's syndrome, and pericarditis lupus.
  • PBMC Peripheral blood mononuclear cells
  • the cells are washed with ice-cold PBS and incubated on ice with the TLRIO-specific polyclonal antibody for 30 min.
  • the cells are gently pelleted, washed with PBS, and incubated with a fluorescent anti-rabbit antibody for 30 min. on ice. After the incubation, the cells are gently pelleted, washed with ice cold PBS, and resuspended in PBS containing 0.1% sodium azide and stored on ice until analysis.
  • Samples are analyzed using a FACScalibur flow cytometer (Becton Dickinson) and CELLQuest software (Becton Dickinson). Instrument settings are determined using FACS-Brite calibration beads (Becton-Dickinson).
  • Tumors expressing TLR10 are imaged using TLRIO-specific antibodies conjugated to a radionuclide, such as 123 I, and injected into the patient for targeting to the tumor followed by X-ray or magnetic resonance imaging.
  • a radionuclide such as 123 I
  • TLR10 Cells expressing TLR10 are identified using antibodies to TLR10, respectively.
  • Polyclonal antibodies are produced by DNA vaccination or by inj ection of peptide antigens into rabbits or other hosts.
  • An animal such as a rabbit, is immunized with a peptide from the extracellular region of TLR10 conjugated to a carrier protein, such as BSA (bovine serum albumin) or KLH (keyhole limpet hemocyanin).
  • BSA bovine serum albumin
  • KLH keyhole limpet hemocyanin
  • Anti- TLRlO antibodies are affinity purified from rabbit serum using a TLRIO peptide, respectively, coupled to Affi-Gel 10 (Bio-Rad), and stored in phosphate-buffered saline (PBS) with 0.1%) sodium azide.
  • an expression vector encoding TLR10 is introduced into mammalian cells. Western blot analysis of protein extracts of non-transfected cells and the TLRlO-containing cells is performed using the polyclonal antibody sample as the primary antibody and a horseradish peroxidase-labeled anti-rabbit antibody as the secondary antibody. Detection of an approximately 89 kD band in the TLRlO-containing cells and lack thereof in the control cells indicates that the polyclonal antibodies are specific for TLR10.
  • Monoclonal antibodies are produced by injecting mice with a TLR10 peptide, with or without adjuvant. Subsequently, the mouse is boosted every 2 weeks until an appropriate immune response has been identified (typically 1-6 months), at which point the spleen is removed. The spleen is minced to release splenocytes, which are fused (in the presence of polyethylene glycol) with murine myeloma cells. The resulting cells (hybridomas) are grown in culture and selected for antibody production by clonal selection. The antibodies are secreted into the culture supernatant, facilitating the screening process, such as screening by an enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • humanized monoclonal antibodies are produced either by engineering a chimeric murine/human monoclonal antibody in which the murine-specific antibody regions are replaced by the human counterparts and produced in mammalian cells, or by using transgenic "knock out" mice in which the native antibody genes have been replaced by human antibody genes and immunizing the transgenic mice as described above.
  • ADCC antibody-dependent cell-mediated cytoxicity
  • Ficoll-Paque gradient centrifugation, and PMN are purified by centrifugation through a discontinuous percoll gradient (70%> and 62%) followed by hypotonic lysis to remove residual erythrocytes.
  • RAl B cell lymphoma cells (for example) are used as target cells.
  • RAl cells are suspended in RPMI 1640 medium supplemented with 2% fetal bovine serum and plated in 96-well V-bottom microtitier plates at 2x 10 4 cells/well.
  • TLRIO-specific antibodies are added in triplicate to individual wells at 1 ⁇ g/ml, and effector cells are added at various effector:target cell ratios (12.5:1 to 50:1). The plates are incubated for 4 hours at
  • Antibodies to TLR10 are conjugated to toxins and the effect of such conjugates in animal models of cancer is evaluated.
  • Chemotherapeutic agents such as calicheamycin and carboplatin, or toxic peptides, such as ricin toxin, are used in this approach.
  • Antibody-toxin conjugates are used to target cytotoxic agents specifically to cells bearing the antigen. The antibody-toxin binds to these antigen-bearing cells, becomes internalized by receptor- mediated endocytosis, and subsequently destroys the targeted cell.
  • the antibody-toxin conjugate targets TLRlO-expressing cells, such as B cell lymphomas, and deliver the cytotoxic agent to the tumor resulting in the death of the tumor cells.
  • toxin that may be conjugated to an antibody
  • carboplatin The mechanism by which this toxin is conjugated to antibodies is described in Ota et al, Asia-Oceania J. Obstet. Gynaecol 19: 449-457 (1993).
  • the cytotoxicity of carboplatin- conjugated TLR9- or TLRIO-specific antibodies is evaluated in vitro, for example, by incubating TLRlO-expressing target cells (such as the RAl B cell lymphoma cell line) with various concentrations of conjugated antibody, medium alone, carboplatin alone, or antibody alone.
  • the antibody-toxin conjugate specifically targets and kills cells bearing the TLR10 antigen, whereas, cells not bearing the antigen, or cells treated with medium alone, carboplatin alone, or antibody alone, show no cytotoxicity.
  • TLRIO-specific antibodies The antitumor efficacy of carboplatin-conjugated TLRIO-specific antibodies is demonstrated in in vivo urine tumor models.
  • Five to six week old, athymic nude mice are engrafted with tumors subcutaneously or through intravenous injection. Mice are treated with the TLRlO-carboplatin conjugate or with a non-specific antibody-carboplatin conjugate.
  • Tumor xenografts in the mouse bearing the TLRIO antigen are targeted and bound to by the TLRlO-carboplatin conjugate, respectively. This results in tumor cell killing as evidenced by tumor necrosis, tumor shrinkage, and increased survival of the treated mice.
  • Other toxins are conjugated to TLRIO-specific antibodies using methods known in the art.
  • An example of a toxin conjugated antibody in human clinical trials is CMA-676, an antibody to the CD33 antigen in AML which is conjugated with calicheamicin toxin
  • Animal models are used to assess the effect of antibodies specific to TLR10 as vectors in the delivery of radionuclides in radio-immunotherapy to treat lymphoma, hematological malignancies, and solid tumors.
  • Human tumors are propagated in 5-6 week old athymic nude mice by injecting a carcinoma cell line or tumor cells subcutaneously.
  • Tumor-bearing animals are injected intravenously with radio-labeled anti-TLRl 0 antibody (labeled with 30-40 ⁇ Ci of 131 I, for example) (Behr, et al, Int. J. Cancer 11: 787-795 (1988)).
  • Tumor size is measured before injection and on a regular basis ⁇ i.e.
  • Anti-tumor efficacy is calculated by correlating the calculated mean tumor doses and the extent of induced growth retardation.
  • animals are sacrificed by cervical dislocation and autopsied. Organs are fixed in 10% formalin, embedded in paraffin, and thin sectioned. The sections are stained with hematoxylin-eosin.
  • mice Animal models are used to evaluate the effect of TLRIO-specific antibodies as targets for antibody-based immunotherapy using monoclonal antibodies.
  • Human myeloma cells are injected into the tail vein of 5-6 week old nude mice whose natural killer cells have been eradicated.
  • mice receive an intraperitoneal injection with TLRIO-specific antibodies either 1 or 15 days after tumor inoculation followed by either a daily dose of 20 ⁇ g or 100 ⁇ g once or twice a week, respectively (Ozaki, et al, Blood 90:3179-3186 (1997)).
  • Levels of human IgG are measured in the murine sera by ELISA.
  • TLRIO-specific antibodies on the proliferation of myeloma cells is examined in vitro using a 3 H-thymidine incorporation assay (Ozaki et al, supra).
  • Cells are cultured in 96-well plates at lxlO 5 cells/ml in 100 ⁇ l/well and incubated with various amounts of TLR9 or TLR10 antibody or control IgG (up to 100 ⁇ g/ml) for 24 h.
  • Cells are incubated with 0.5 ⁇ Ci 3 H-thymidine (New England Nuclear, Boston, MA) for 18 h and harvested onto glass filters using an automatic cell harvester (Packard, Meriden, CT). The incorporated radioactivity is measured using a liquid scintillation counter.
  • the cytotoxicity of the TLRl 0 monoclonal antibody is examined by the effect of complements on myeloma cells using a 51 Cr-release assay (Ozaki et al, supra).
  • Myeloma cells are labeled with 0.1 mCi Cr-sodium chromate at 37°C for 1 h.
  • Cr-labeled cells are incubated with various concentrations of TLR10 monoclonal antibody or control IgG on ice for 30 min. Unbound antibody is removed by washing with medium. Cells are distributed into 96-well plates and incubated with serial dilutions of baby rabbit complement at 37°C for 2 h.
  • the supematants are harvested from each well and the amount of 51 Cr released is measured using a gamma counter. Spontaneous release of 51 Cr is measured by incubating cells with medium alone, whereas maximum 51 Cr release is measured by treating cells with 1% NP-40 to disrupt the plasma membrane. Percent cytotoxicity is measured by dividing the difference of experimental and spontaneous 51 Cr release by the difference of maximum and spontaneous 51 Cr release.
  • Antibody-dependent cell-mediated cytotoxicity (ADCC) for the TLR10 monoclonal antibody is measured using a standard 4 h 51 Cr-release assay (Ozaki et al, supra). Splenic mononuclear cells from SCID mice are used as effector cells and cultured with or without recombinant interleukin-2 (for example) for 6 days. 51 Cr-labeled target myeloma cells (l lO 4 cells) are placed in 96-well plates with various concentrations of anti-TLRl 0 monoclonal antibody or control IgG. Effector cells are added to the wells at various effector to target ratios (12.5:1 to 50:1).
  • Animal models are used to assess the effect of TLRIO-specific antibodies on blocking signaling through the TLRIO receptor to suppress autoimmune diseases, such as arthritis or other inflammatory conditions, or rejection of organ transplants.
  • immunosuppression is tested by injecting mice with horse red blood cells (HRBCs) and assaying for the levels of HRBC-specific antibodies (Yang, et al, Int. Immunopharm. 2:389- 397 (2002)). Animals are divided into five groups, three of which are injected with anti- TLRl 0 antibodies for 10 days, and 2 of which receive no treatment. Two of the experimental groups and one control group are injected with either Earle's balanced salt solution (EBSS) containing 5-10xl0 7 HRBCs or EBSS alone.
  • EBSS Earle's balanced salt solution
  • Anti-TLRlO antibody treatment is continued for one group while the other groups receive no antibody treatment.
  • all animals are bled by retro-orbital puncture, followed by cervical dislocation and spleen removal.
  • Splenocyte suspensions are prepared and the serum is removed by centrifugation for analysis.
  • hnmunosupression is measured by the number of B cells producing HRBC-specific antibodies.
  • the Ig isotype (for example, IgM, IgGl, IgG2, etc.) is determined using the IsoDetectTM Isotyping kit (Stratagene, La Jolla, CA). Once the Ig isotype is known, murine antibodies against HRBCs are measured using an ELISA procedure.
  • 96-well plates are coated with HRBCs and incubated with the anti-HRBC antibody-containing sera isolated from the animals.
  • the plates are incubated with alkaline phosphatase-labeled secondary antibodies and color development is measured on a microplate reader (SPECTRAmax 250, Molecular Devices) at 405 nm using >-nitrophenyl phosphate as a substrate.
  • SPECTRAmax 250 Molecular Devices
  • Lymphocyte proliferation is measured in response to the T and B cell activators concanavalin A and lipopolysaccharide, respectively (Jiang, et al, J. Immunol. 154:3138- 3146 (1995).
  • Mice are randomly divided into 2 groups, 1 receiving anti-TLRlO antibody therapy for 7 days and 1 as a control.
  • the animals are sacrificed by cervical dislocation, the spleens are removed, and splenocyte suspensions are prepared as above.
  • the anti-TLRl 0 antibody is added to the medium at the beginning of the experiment.
  • Assays are carried out to assess activity of fragments of the TLRIO protein, such as the Ig domain, to stimulate cytokine secretion and to stimulate immune responses in NK cells, B cells, T cells, and myeloid cells.
  • Such immune responses can be used to stimulate the immune system to recognize and/or mediate tumor cell killing or suppression of growth.
  • this immune stimulation can be used to target bacterial or viral infections.
  • fragments of the TLRIO that block activation through the TLRIO receptor maybe used to block immune stimulation in natural killer (NK), B, T, and myeloid cells.
  • Fusion proteins containing fragments of the TLRIO, such as the Ig domain (TLR10- Ig), are made by inserting a CD33 leader peptide, followed by a TLRIO domain fused to the Fc region of human IgGl into a mammalian expression vector, which is stably transfected into NS-1 cells, for example.
  • the fusion proteins are secreted into the culture supernatant, which is harvested for use in cytoldne assays, such as interferon- ⁇ (LFN- ⁇ ) secretion assays (Martin, et al, J. Immunol. 167:3668-3676 (2001)).
  • PBMCs are activated with a suboptimal concentration of soluble CD3 and various concentrations of purified, soluble anti-TLRl 0 monoclonal antibody or control IgG.
  • TLRIO-Ig cytokine assays anti-human Fc Ig at 5 or 20 ⁇ g/ml is bound to 96-well plates and incubated overnight at 4°C. Excess antibody is removed and either TLRIO-Ig or control Ig is added at 20-50 ⁇ g/ml and incubated for 4 h at room temperature. The plate is washed to remove excess fusion protein before adding cells and anti-CD3 to various concentrations. Supematants are collected after 48 h of culture and LFN- ⁇ levels are measured by sandwich ELISA, using primary and biotinylated secondary anti-human IFN-7 antibodies as recommended by the manufacturer.
  • TLRIO-specific antibodies are used for imaging TLRlO-expressing cells in vivo.
  • Six-week-old athymic nude mice are irradiated with 400 rads from a cesium source. Three days later the irradiated mice are inoculated with 4xl0 7 RAl cells and 4xl0 6 human fetal lung fibroblast feeder cells subcutaneously in the thigh. When the tumors reach approximately 1 cm in diameter, the mice are injected intravenously with an inoculum containing 100 ⁇ Ci/10 ⁇ g of 13 ⁇ -labeled TLRIO-specific antibody. At 1, 3, and 5 days postinj ection, the mice are anesthetized with a subcutaneous injection of 0.8 mg sodium pentobarbital. The immobilized mice are then imaged in a prone position with a Spectrum
  • IL set to record 5,000 to 10,000 counts using the Nuclear MAX Plus image analysis software package (MEDX Inc.; Wood Dale, IL) (Homick, et al, Blood 89:4437-4447
  • This example describes an exemplary clinical study in patients with recurrent B cell lymphoma. Similar studies are also contemplated to be performed on patients with other cancers and diseases relating to TLR10 expression.
  • This study is directed to patients with relapsed non-Hodgkin's lymphoma with measurable disease after at least one prior course of standard therapy.
  • a tumor biopsy is performed to document tumor cell expression of the TLR10 antigen of the invention and reactivity with an antibody that reacts with said antigen using flow cytometry.
  • baseline hematologic function (1500 granulocytes and 50,000 platelets/ ⁇ l), renal function (serum creatine of ⁇ 2.5 mg/dl), quantitative serum IgG of greater than 600 mg/dl, a negative serology to human immunodeficiency virus (HIV), a negative hepatitis B surface antigen, a life expectancy of at least 3 months without other serious illness, and between the ages of 18 and 75 years.
  • HAV human immunodeficiency virus
  • TLR10 expression is determined on all cases before antibody treatment by flow cytometry of fresh or cryopreserved tumor cell suspensions. Tumor cells are obtained from excisional biopsies or from fine needle tumor aspirations and stained for said TLR10 expression with fluorescently-labeled anti-TLRl 0 antibodies.
  • Tumor cells are also analyzed for expression of surface Ig light chains (fluorescent (FITC)-goat F(ab) -anti-human K or ⁇ ; Tago, Buriingame, CA), CD19, CD4, CD3, CD8 (FITC- or phycoerythrin (PE)-conjugated Leul2, Leu3, Leu4, and Leu2;Becton Dickinson), and CD37 (MBI clone 6A4).
  • FITC fluorescent
  • PE phycoerythrin
  • Peripheral blood samples are analyzed for the number of cells expressing the TLR10 antigen using two color flow cytometry using PE or FITC conjugates of the above reagents.
  • Two week post-treatment tumor biopsies are also evaluated for B- and T- cell content using the same reagents described above.
  • Antibody bound to tumor cells from in vivo administration is detected by a combination of two different methods.
  • cells are stained using FITC-labeled anti-TLRlO antibodies.
  • the presence of the unlabeled antibody blocks the binding of the labeled antibody, resulting in decreased immunostaining of the B-cell tumor population (as identified using antibodies to additional B-cell antigens CD19, CD37, IgM, IgG, K or ⁇ ).
  • the bound chimeric antibody is detected directly by looking for IgM ⁇ -ox ⁇ -positive tumor cells now bearing the human IgG ( ) constant regions of the chimeric antibody using a FITC labeled goat F(ab') 2 anti-human IgG ⁇ -chain- specific reagent (Tago).
  • An estimate of the percentage of tumor cells with the chimeric antibody attached is obtained by comparing the staining of the pretreatment and the post- treatment biopsies for human IgG constant regions.
  • Serum levels of the chimeric antibody are determined using an enzyme-linked immunosorbant assay (ELISA).
  • ELISA enzyme-linked immunosorbant assay
  • Microtiter plates are coated with a purified polyclonal anti- TLRl 0 idiotype antiserum. After washing and blocking, post-treatment sera are serially diluted.
  • Bound human IgG is detected using an HRP-conjugated polyclonal anti-human IgG reagent, and the plates are developed with the substrate 2,2-azinobis(3-ethylbenzthiazoline sulfonic acid) (ABTS).
  • Antibody concentration is determined by comparison of the signal from the patients sera with that obtained from known concentrations of purified chimeric antibody diluted into normal human serum.
  • Post-treatment sera from evaluations at 1, 2, and 3 months are analyzed for evidence of a host anti-chimeric antibody immune response using a sandwich ELISA with microtiter plates coated with anti-TLRl 0 antibody, the murine anti-TLRl 0 antibody, or normal murine IgG. Dilutions of the patients sera are added and, after washing, are detected with biotin- labeled chimeric antibody followed by Avidin-HRP and the substrate ABTS. This assay has a level of quantification of 5 ⁇ g/ml.
  • NCICT Common Toxicity
  • a minor response is defined as a 25% to 50% reduction in disease.
  • Stable disease is defined as no significant change in tumor measurements without progression over the period of observation.
  • Progressive disease is noted when there is a 25% increase in measurable disease or the appearance of any new lesion.
  • This example describes an exemplary clinical study in patients with recurrent B cell lymphoma. Similar studies are also contemplated to be performed on patients with other cancers and diseases relating to TLRIO expression.
  • Eligibility criteria include TLRlO-positive B-cell lymphoma at first or higher relapse or progressive disease after at least one standard treatment. Lesions are classified as TLR10- positive when the TLRIO antigen of the invention is expressed on more than 30% of malignant cells. All histologic slides are reviewed by an independent expert panel consisting of 6 reference pathologists. For enrollment into the study, patients also have to meet the following requirements: have a bidimensionally measurable disease, at least one lesion larger than 1.0 cm in its greatest diameter, and a World Health Organization performance status of 0, 1, or 2. In addition, patients have to be at least 18 years of age, neither pregnant nor lactating, using accepted birth control methods, and have to have a life expectancy of 3 months or longer. Patients with major organ dysfunction or active infections are excluded from this study. Prior treatment with anti-TLRl 0 antibodies is also an exclusion criterion. Concurrent therapeutic use of corticosteroids is not allowed.
  • This phase 2 trial is designed to evaluate the feasibility of single-dose anti-TLRl 0 antibody in patients with B-cell lymphoma and to document possible anti-tumor effects (for protocol details see Rehwald et al, Blood 101 :420-424 (2003), herein incorporated by reference in its entirety). Patients are evaluated when completing at least 2 infusions of anti- TLRl 0 antibody. For the efficacy analysis the best response achieved from the start of treatment to progressive disease is recorded. The response rates (overall objective and complete response rates) are reported in rates with 95% confidence intervals (Pearson Clopper intervals).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une thérapie de ciblage utilisant des polypeptides TLR10, des acides nucléiques codant pour des polypeptides TLR10, des anticorps anti-TLR10, qui fournit un procédé qui élimine ou qui inhibe la croissance de cellules cancéreuses exprimant la protéine TLR10. L'invention concerne des procédés de thérapie et de diagnostic de troubles liés aux cellules exprimant la protéine TLR10.
PCT/US2003/036971 2002-11-22 2003-11-19 Procédés de thérapie et de diagnostic WO2004047612A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002506356A CA2506356A1 (fr) 2002-11-22 2003-11-19 Procedes de therapie et de diagnostic
EP03786850A EP1567863A4 (fr) 2002-11-22 2003-11-19 Procedes de therapie et de diagnostic
AU2003295649A AU2003295649A1 (en) 2002-11-22 2003-11-19 Methods of therapy and diagnosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/302,444 US20040022786A1 (en) 2000-01-21 2002-11-22 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US10/302,444 2002-11-22
US10/327,491 2002-12-19
US10/327,491 US20040023870A1 (en) 2000-01-21 2002-12-19 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US64122203A 2003-08-13 2003-08-13
US10/641,222 2003-08-13

Publications (2)

Publication Number Publication Date
WO2004047612A2 true WO2004047612A2 (fr) 2004-06-10
WO2004047612A3 WO2004047612A3 (fr) 2005-04-14

Family

ID=32397926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036971 WO2004047612A2 (fr) 2002-11-22 2003-11-19 Procédés de thérapie et de diagnostic

Country Status (4)

Country Link
EP (1) EP1567863A4 (fr)
AU (1) AU2003295649A1 (fr)
CA (1) CA2506356A1 (fr)
WO (1) WO2004047612A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014653A1 (fr) * 2004-07-20 2006-02-09 Schering Corporation Induction de l'apoptose dans des cellules tumorales exprimant des recepteurs toll-like (tlr)
KR101250127B1 (ko) 2004-07-09 2013-04-02 바이엘 파마 악티엔게젤샤프트 Ｂ-세포 림프종의 치료를 위한 방사성표지된 안티-ｃｄ20항체와의 병용요법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1070399A (en) * 1997-10-17 1999-05-10 Genentech Inc. Human toll homologues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [Online] 02 August 1999 GODDARD ET AL.: 'Human toll protein PRO358', XP002999283 Database accession no. AAY05868 *
DATABASE GENBANK [Online] 05 April 2000 BAKER ET AL.: 'Membrane-bound protein PRO358', XP002999284 Database accession no. AAY66644 *
DATABASE GENBANK [Online] 27 March 2001 CHUANG ET AL.: 'Homo sapiens too-like receptor 10 mRNA, complete cds', XP002999281 Retrieved from EMBL Database accession no. AF296673 *
DATABASE GENESEQ [Online] 26 March 2002 HARDIMAN ET AL.: 'Human DNAS toll like receptor (DTLR) 8 cDNA #3', XP002999282 Database accession no. AAD26299 *
See also references of EP1567863A2 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101250127B1 (ko) 2004-07-09 2013-04-02 바이엘 파마 악티엔게젤샤프트 Ｂ-세포 림프종의 치료를 위한 방사성표지된 안티-ｃｄ20항체와의 병용요법
WO2006014653A1 (fr) * 2004-07-20 2006-02-09 Schering Corporation Induction de l'apoptose dans des cellules tumorales exprimant des recepteurs toll-like (tlr)
JP2008507530A (ja) * 2004-07-20 2008-03-13 シェーリング　コーポレイション Ｔｏｌｌ様受容体を発現する腫瘍細胞におけるアポトーシスの誘導
AU2005269733B2 (en) * 2004-07-20 2008-10-30 Schering Corporation Induction of apoptosis in Toll-like receptor expressing tumor cells

Also Published As

Publication number Publication date
CA2506356A1 (fr) 2004-06-10
AU2003295649A1 (en) 2004-06-18
EP1567863A4 (fr) 2007-10-03
WO2004047612A3 (fr) 2005-04-14
EP1567863A2 (fr) 2005-08-31

Similar Documents

Publication Publication Date Title
US20050281813A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20040023870A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US7378253B2 (en) Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
US20030215453A1 (en) Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US20090081209A1 (en) Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
WO2005079490A2 (fr) Procedes de therapie et de diagnostic reposant sur le ciblage de cellules qui expriment les polypeptides steap2
US20090220416A1 (en) Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
US20050095237A1 (en) Methods of therapy and diagnosis using targeting of cells that express P2Y10
WO2004053061A2 (fr) Procedes d'immunotherapie et de diagnostic par ciblage de cellules exprimant des proteines lax
EP1583777A2 (fr) Procedes de therapie et de diagnostic utilisant le ciblage de cellules d'expression de ly-9
WO2004047612A2 (fr) Procédés de thérapie et de diagnostic
WO2003068935A2 (fr) Méthodes thérapeutiques et diagnostiques
US20050129697A1 (en) Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
AU2003213064B2 (en) Methods of therapy and diagnosis
US20040022786A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
WO2004094607A2 (fr) Methodes de therapie et de diagnostic utilisant le ciblage de cellules qui expriment une proteine du type transporteur humaine
US20040109862A1 (en) Methods of therapy and diagnosis using targeting of cells that express Ly-9
AU2007234602A1 (en) Methods of therapy and diagnosis
JP2007512836A (ja) キラー細胞免疫グロブリン様レセプター様タンパク質を発現する細胞の標的化を用いる治療および診断の方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003295649

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2506356

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003786850

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003786850

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP